University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2016

The Role Of Antibody Subclass In The Pathogenesis Of
Pemphigus Vulgaris
Eric Milan Mukherjee
University of Pennsylvania, eric.mukherjee@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Bioinformatics Commons, Genetics Commons,
Immunology and Infectious Disease Commons, and the Medical Immunology Commons

Recommended Citation
Mukherjee, Eric Milan, "The Role Of Antibody Subclass In The Pathogenesis Of Pemphigus Vulgaris"
(2016). Publicly Accessible Penn Dissertations. 2709.
https://repository.upenn.edu/edissertations/2709

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2709
For more information, please contact repository@pobox.upenn.edu.

The Role Of Antibody Subclass In The Pathogenesis Of Pemphigus Vulgaris
Abstract
A marvel of evolution, the adaptive immune system has the capacity to respond to almost any foreign
antigen in a highly specific manner. Antibodies, Y-shaped glycoproteins containing both diverse variable
regions responsible for antigen binding and constant regions responsible for effector function, are a key
part of this capacity. However, this vast diversity comes with several drawbacks, one of which is the fact
that the immune system can deleteriously respond to self-antigens. The focus of this thesis is to
characterize the role of class-switching (the changing of antibody constant regions) in the pathogenesis
of autoimmune disease, and in particular to trace the lineage of antigen-specific autoreactive B cells by
analyzing clonal relationships between antibodies of different constant regions. Analyzing such lineages
has the potential to shed light on mechanisms of autoantibody-mediated disease pathogenesis, leading
to better understanding of autoimmunity and better therapeutics.
The work presented in this thesis focuses on pemphigus vulgaris, or PV, a model antibody-mediated
autoimmune disease characterized by a response to the cell adhesion protein desmoglein (Dsg) 3, which
holds keratinocytes together in the epidermis. An enigmatic feature of this disease is the predominance
of antibodies from the IgG4 subclass during active disease, which ordinarily appears to have few effector
functions and may serve as a “brake” on the immune system in the setting of continuous stimulation by
antigen. PV patients also display autoantibodies of the IgG1 subclass during disease and remission, but
the relationship between IgG1 and IgG4 in the disease in unclear. Because the majority of cases of PV
also harbor anti-Dsg antibodies of the IgA1 and IgA2 subclasses, we sought to determine the
relationships between autoantibodies belonging to each of these subclasses. First, we address whether
the same anti-Dsg variable region, grafted onto either IgG1 or IgG4 constant regions, can show differing
affinity or pathogenicity, in order to determine whether antibody subclass is directly modulating
pathogenic effect (chapter 2). Finding that the subclass has very little effect on antibody affinity,
pathogenicity, or epitope preference, we then sought to determine whether B cells expressing
autoantibodies of different subclasses share lineages, indicating common pathways of development
(chapter 3). Using a combination of antigen-specific antibody cloning through phage display, and nextgeneration sequencing of subclass specific repertoires in a panel of PV patients, we managed to trace 80
lineages of anti-Dsg B cells across all four subclasses tested. In particular, we found that anti-Dsg IgG4 B
cells, which are believed to be central to disease pathogenesis, tended to not share lineages with other
subclasses, and in in general do not appear to share a precursor-product relationship with anti-Dsg IgG1 B
cells. We have also found that anti-Dsg IgA1 and IgA2 were tightly related and often arose directly from
IgG precursors. These findings are key to understanding the role of class-switching in the pathogenesis of
PV, and may shed light on the class-switch mechanisms driving other autoimmune diseases and states of
chronic antigen stimulation.
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ABSTRACT
A marvel of evolution, the adaptive immune system has the capacity to respond
to almost any foreign antigen in a highly specific manner. Antibodies, Y-shaped
glycoproteins containing both diverse variable regions responsible for antigen binding
and constant regions responsible for effector function, are a key part of this capacity.
However, this vast diversity comes with several drawbacks, one of which is the fact that
the immune system can deleteriously respond to self-antigens. The focus of this thesis is
to characterize the role of class-switching (the changing of antibody constant regions) in
the pathogenesis of autoimmune disease, and in particular to trace the lineage of
antigen-specific autoreactive B cells by analyzing clonal relationships between
antibodies of different constant regions. Analyzing such lineages has the potential to
shed light on mechanisms of autoantibody-mediated disease pathogenesis, leading to
better understanding of autoimmunity and better therapeutics.
The work presented in this thesis focuses on pemphigus vulgaris, or PV, a model
antibody-mediated autoimmune disease characterized by a response to the cell
adhesion protein desmoglein (Dsg) 3, which holds keratinocytes together in the
epidermis. An enigmatic feature of this disease is the predominance of antibodies from
the IgG4 subclass during active disease, which ordinarily appears to have few effector
functions and may serve as a “brake” on the immune system in the setting of
continuous stimulation by antigen. PV patients also display autoantibodies of the IgG1
subclass during disease and remission, but the relationship between IgG1 and IgG4 in
the disease in unclear. Because the majority of cases of PV also harbor anti-Dsg
iii

antibodies of the IgA1 and IgA2 subclasses, we sought to determine the relationships
between autoantibodies belonging to each of these subclasses. First, we address
whether the same anti-Dsg variable region, grafted onto either IgG1 or IgG4 constant
regions, can show differing affinity or pathogenicity, in order to determine whether
antibody subclass is directly modulating pathogenic effect (chapter 2). Finding that the
subclass has very little effect on antibody affinity, pathogenicity, or epitope preference,
we then sought to determine whether B cells expressing autoantibodies of different
subclasses share lineages, indicating common pathways of development (chapter 3).
Using a combination of antigen-specific antibody cloning through phage display, and
next-generation sequencing of subclass specific repertoires in a panel of PV patients, we
managed to trace 80 lineages of anti-Dsg B cells across all four subclasses tested. In
particular, we found that anti-Dsg IgG4 B cells, which are believed to be central to
disease pathogenesis, tended to not share lineages with other subclasses, and in in
general do not appear to share a precursor-product relationship with anti-Dsg IgG1 B
cells. We have also found that anti-Dsg IgA1 and IgA2 were tightly related and often
arose directly from IgG precursors. These findings are key to understanding the role of
class-switching in the pathogenesis of PV, and may shed light on the class-switch
mechanisms driving other autoimmune diseases and states of chronic antigen
stimulation.
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CHAPTER 1:
Introduction

Adaptive immunity in higher vertebrates, like humans, relies on generating
highly diverse antibody molecules capable of responding to almost any target. While
conferring protection against a variety of antigens, the adaptive immune system also
has the power to respond to self-antigens, causing autoimmunity. As a geneticist, I view
the adaptive immune system as a Darwinian mechanism, searching through a
staggeringly diverse space of biological sequences. This can be analogized as a group of
evolving and mutating B cells walking through an antibody-encoding Library of Babel *,
finding useful, protective antibody sequences amongst a vast background of irrelevant
and potentially dangerous ones. The focus of my thesis work has been understanding
the development, lineage, and sequence properties of autoreactive B cells in the model
antibody-mediated autoimmune disease pemphigus vulgaris, to better understand the
pathogenesis of autoimmunity. Separating the features of autoreactive cells from the
larger repertoire will not only shed light on the pathogenesis of autoimmune disease, it
may also help design better treatment strategies for the ever-increasing population of
autoimmune disease sufferers worldwide (5).

The Library of Babel is a short story by the Argentinian author Jorge Luis Borges(1). It considers a fictional
universe containing all possible 410-page books housed in an “indefinite, perhaps infinite” number of
linked hexagonal rooms. A similar analogy has been used to describe the total space of DNA or protein
sequences by the philosopher Daniel Dennett (calling it the “Library of Mendel”)(2) and others (3)(4).

*
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1.1 Antibody Development
1.1.1 Introduction
Antibodies, or immunoglobulins (Ig), are highly diverse glycoproteins generated
as a key component of the adaptive immune system in higher vertebrates (6). The
antibody macromolecule consists of four polypeptide chains, with two heavy and two
light chains linked together by disulfide bonds forming a Y shape. The variable region of
each monomer is contributed to by both the heavy and light chain, and serves to
recognize and bind to antigen. The constant region, by contrast, determines the isotype
and effector function of each antibody. The genesis, development and genetic basis of
antibody constant and variable region diversity will be described in this section.

1.1.2 Antibody Genesis
In humans, the peptides that comprise a mature antibody are encoded by
separate Ig loci located on chromosome 14 (heavy chain, IgH), chromosome 2 (kappa
light chain, IgK), and chromosome 22 (lambda light chain, IgL)(7)(8)(9). During
development, each B-cell precursor rearranges these loci in a stepwise process called
V(D)J recombination, so named because each Ig heavy chain locus contains several
variable (V), diversity (D), and joining (J) segments that will be joined together to
generate a contiguous immunoglobulin-coding DNA segment (10)(11). The light chain
loci have a similar architecture and are rearranged in a similar fashion, though without
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the D genes; therefore, the final heavy chain of an antibody is coded by three apposed
gene segments, while the light chain is coded by two.
Hematopoietic stem cells in the bone marrow differentiate into multipotent
progenitors, then common lymphoid progenitors (CLP), then pro-B cells, which are
committed to the B cell lineage via the expression of the transcription factor Pax5 (12).
At the pro-B cell stage, the Ig loci have not yet been made productive. At this point,
transcription factors including BCL11A/B, FOG1, and FOG2 induce expression of the
heterodimeric RAG1/2 recombinase, which initiates the process of VDJ recombination at
the heavy chain locus (13)(14)(15)(16). First, a D gene and J gene are randomly selected,
and RAG1/2 creates a double-strand break in the recombination signal sequences (RSS)
adjacent to the selected D and J exons; the intervening segment is ligated to form a
circular intermediate called the signal end complex, and the sequence adjacent to the D
and J genes self-anneal to form hairpin structures (17)(18)(19). At this stage, the Artemis
nuclease nicks and opens each hairpin, which generates a linear stretch of DNA
containing palindromic (P) nucleotides (so-called since hairpins necessarily have
palindromic sequences to self-anneal). This stretch of P nucleotides can subsequently be
chewed back by variety of exonucleases to chew back the DNA, and/or extended by
terminal deoxynucleotidyl transferase (TdT), which adds non-template (N) nucleotides
adjacent to the original P nucleotides to generate additional diversity
(20)(21)(22)(23)(24)(25). Subsequently, these two D and J genes are recombined
together in an error-prone process of non-homologous end-joining (NHEJ)(26)(27). The
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same process then occurs between a selected V gene and the DJ segment, creating one
continuous VDJ region encoding the heavy chain variable region (Figure 1-1) (28).
At this stage, the mature heavy chain with an IgM constant region, paired with a
surrogate light chain, is expressed on the surface of the developing B cell as part of the
pre-B cell receptor (pre-BCR), along with invariant Ig-alpha and Ig-beta signaling
molecules (29). Signaling through this receptor, which is only possible when the product
of the heavy chain locus can successfully pair with the surrogate light chain, ends VDJ
recombination at the IgH locus by down-regulating RAG1/2 (30)(31)(32) . Furthermore,
signaling at this step ensures that only one antibody heavy chain is expressed per B cell,
in a process called allelic exclusion (33)(34)(35). This signaling allows the pro-B cell to
transition to a pre-B cell, which subsequently divides repeatedly and rearranges its light
chain locus in a similar fashion (Figure 1-2). In this stage, the pre-B cell does not yet
express mature IgM on its surface, but does show cytoplasmic IgM heavy chains, which
are rapidly degraded as they cannot yet pair with a mature light chain (36). After the
light chain rearranges and pairs properly with the already-rearranged heavy chain, the
pre-B cell becomes an immature B-cell and expresses a mature BCR complex on its
surface (37). After crossing a few critical checkpoints detailed in section 1.1.5, immature
B-cells move to the periphery, where they can divide and diversify to give rise to clonal
lineages originating from a single VDJ recombination event. These later steps of
antibody maturation and diversification in the periphery are discussed in later sections
of this chapter.

4

Note that at the point of the B cell exiting the bone marrow, there are three key
sources of sequence diversity in the variable heavy chain. First, the combinatorial
diversity generated by selecting different V, D and J genes is substantial. According to
the IMGT database, in the human IgH locus, there are 38-46 * functional V genes, 23
functional D genes, and 6 J genes, generating 4002-5244 different joins (39)(40)(41).
Human light chains are encoded by 29-33 V and 4-5 J chains in the lambda locus or 3135 V and 5 J chains at the kappa locus, for a total of 271-340 different joins
(41)(42)(43)(44). Random pairing of heavy and light chains generates a final
combinatorial diversity of between 1.08 x 106 and 1.78 x 106. This is further increased by
the imprecise nature of each V-D and D-J join in the heavy chain and V-J joins in the light
chain, resulting in a final naïve B-cell repertoire diversity of approximately 1011 in a
single individual and theoretically greater than 1014 across the entire space of variable
region sequences (45)(46)(47).
However, this diversity comes at a significant cost. The NHEJ mechanism doesn’t
take reading frame into account, meaning that approximately two-thirds of
recombination events will not produce functional protein (48)(49). When these
nonproductive rearrangements fail to signal through the pre-BCR complex, they can be
rescued by subsequent rearrangements on the same chromosome (selecting V genes
upstream or J genes downstream of the unproductive VDJ locus) or, if those options are

IMGT reports a range, because there’s variability from person to person in the number of functional V,
D, and J genes in each locus. The loci also contain non-functional ORFs (which have an open reading frame
but lack other features needed for function) and pseudogenes (which contain stop codons or frameshifts).
For more information on the variability in the germline VDJ complement, please see (38)
*
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exhausted, by subsequent rearrangement on the other chromosome. A similar process
occurs in the light chain locus at the pre-B cell stage, resulting in a productive V-J
rearrangement from either the lambda or kappa locus and isotypic exclusion of the
other (35)(50). In sum, this results in approximately half of all pro-B cells going on to
produce functional antibody (41).
The sequence structure of a mature antibody variable region gives some insight
into its function (Figure 1-3). Each heavy and light chain can be divided into three loopshaped hypervariable complementarity-determining regions (CDRs) interspersed with
relatively rigid beta sheets called framework regions (FWRs) (51)(52). In general, CDRs
are responsible for the antigen specificity of a given antibody, while the FWRs are
responsible for stabilizing the antibody’s three-dimensional structure, though this
distinction isn’t absolute (53)(54)(55)(56)(57)(58). CDR1 and CDR2 are entirely encoded
by the V gene in both the heavy and light chain, and the CDR3 spans the V-J junction in
the light chain and the V-D-J junction in the heavy chain. Because the CDR3 spans all
segments and the junctional diversity therein, it is almost impossible for two
independent pro-B cells to give rise to the same heavy chain CDR3 region after
recombination, and therefore the CDR3 is commonly used as a marker of clonal
relatedness between B cells (59).
As the B cell circulates and migrates into secondary lymphoid organs, it
undergoes further diversification through two processes, somatic hypermutation and
class switching. These processes, and their effects on the repertoire, will be described in
the following sections.
6

1.1.3 Variable Region Development
Immature B cells further differentiate into transitional B cells as they exit the
bone marrow (60)(61). At this stage, the transitional B cell migrates to follicles in
secondary lymphoid organs (lymph node, spleen, Peyer’s patches in the ileum, etc.).
Either during or after its migration, the transitional B cell further differentiates into a
mature naïve B cell, capable of responding to antigen and co-stimulatory signals
(61)(62). At this stage, the B cell can enter a germinal center (GC) within a secondary
lymphoid organ, which are sites of rapid B cell proliferation and differentiation (63).
Before entering the GC, B cells can bind to and endocytose circulating antigen using its
BCR, subsequently presenting linear peptides derived from said antigen on their surface
using major histocompatibility complex (MHC) (64)(65). At this point, the antigenexperienced B cell can enter the GC, where it can form an immunological synapse with a
helper T cell (TH cell) expressing a cognate T-cell receptor (TCR) for the same antigen **
(67)(68). Through this MHC:TCR interaction, as well as co-stimulatory ligand-receptor
interactions like CD40:CD40L, CD80:CD28, and CD86:CD28, the antigen-experienced B
cell undergoes clonal expansion and further maturation, fine-tuning its affinity for its
target antigen (69)(70)(71)(72).
The key molecule that catalyzes B cell affinity maturation is Activation-Induced
Cytidine Deaminase (AID), a tightly-controlled enzyme which catalyzes C-to-U deamination in the IgH, IgL, and/or IgK variable regions in a transcription-dependent

TCRs undergo a similar VDJ recombination process as antibodies, though their function is to respond to
linear peptides displayed on MHC molecules by antigen-presenting cells. The theoretical maximum of TCR
diversity approaches 1020, though humans only have ~1012 total T cells. For more information, see (66)
**
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manner (73)(74)(75)(76). The subsequent G:U mismatch can be dealt with after
MSH2/MSH6 binding by the mismatch repair, or by uracil-DNA glycosylase creating an
abasic site that is subsequently filled by base excision repair (77)(78)(79)(80). The
former pathway can also induce mutations in nearby A/T residues on the same strand
by recruiting the error-prone DNA polymerase eta (81)(82). This process, called somatic
hypermutation (SHM), creates point mutations across the variable region, substantially
increasing the total sequence space available to the immune system for antigen binding
and antigen-driven selection. Mutations that increase the affinity of the BCR are
subsequently selected and propagated by outcompeting lower-affinity sequences for
limited T cell help, resulting in a clonally-related B cell pool with greatly increased
affinity for the target antigen (83). These affinity-matured B cells can undergo further
differentiation into plasma cells and memory cells (84). The former take up long-term
residence in specified niches in the bone marrow, mucosa-associated lymphoid tissue
(MALT), and spleen and secrete soluble antibody into the bloodstream and lymphatic
system like so much biochemical artillery, while the latter express matured antibody in a
transmembrane form, lying in wait to respond when re-challenged with the same
antigen (85)(86)(87).
There also exists an alternative pathway for B cell maturation outside the GC,
called the “extrafollicular pathway”, where B cells can mature without T cell help. This
pathway is particularly important in first-line defenses requiring rapid production of
antibody, and appears to function as part of the innate immune system. For example, in
the marginal zone of the spleen, which samples antigens from circulation, simultaneous
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engagement of toll-like receptors (TLRs) and BCR on the B cell surface can serve as a costimulatory signal, allowing B cell activation and differentiation into antibody-secreting
plasma cells in the absence of T cells (88)(89). Antigen-presenting dendritic cells, which
reside in areas in contact with the environment, can also directly induce activation and
class switching by engaging BCR and secreting the B cell activating factors BLyS and
APRIL (90). Finally, intestinal epithelial cells can sense bacterial antigens in the gut
through TLRs, secreting APRIL and activating dendritic cells to induce T-independent
class switch to IgA (91). In general, these extrafollicular responses create low-affinity
antibodies with fewer somatic mutations than in B cells that pass through the GC,
making these two repertoires, in theory, distinguishable (92,93).
Mutations induced during SHM are not perfectly uniform across the variable
region, for a variety of reasons. AID preferentially mutates cytosines belonging to the
“hotspot” motifs WRCY/RGYW and avoids cytosines in the SYC/GRS “coldspot” motif
(94)(95)(96)(97). A secondary SHM hotspot, WA/TW, is due to DNA polymerase eta
activity (98)(99)(100). High-throughput sequencing work has largely corroborated this
hotspot-coldspot model, with the additional complication that hotspots can show a
wide range of “hotness”, i.e. mutability (101). It has also been shown that through
evolutionary pressure, hotspot motifs, and in particular hotspot motifs in which the
mutable cytosine is in a position likely to result in amino acid replacement upon
mutation, have been preferentially clustered into the CDR regions, while coldspot motifs
segregate to FWR regions (102)(103)(104)(105). In theory, this ensures that SHM
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preferentially mutates sections of the variable region responsible for antigen-binding,
and avoids regions required for structural integrity.
In addition to point mutations, SHM can also add insertions and deletions
(indels) to the variable region (106). Up to 6.5% of circulating B-cells encode indelcontaining antibody variable regions; though rare, they add substantially to the overall
diversity of the antibody repertoire (107). Indels tend to occur near AID hotspots, tend
to localize to CDRs or CDR-adjacent residues, and rapidly decrease in frequency with
length (108)(109). While the exact mechanism of indel creation isn’t known, in vitro
studies have shown that AID is necessary for this mechanism of diversification (107),
and in vivo studies have shown that indels preferentially occur in repetitive or loopforming tracts of DNA near AID hotspots, suggesting a model in which a repair
polymerase “slips” while correcting an AID-induced mutation, either creating a deletion
or duplicating adjacent nucleotides to create an insertion (110).
SHM-induced indels allow the adaptive immune system to sample relatively
inaccessible regions of sequence space; those B cells fortunate enough to reach these
obscure rooms in the library can produce antibodies with particularly interesting
reactivity. For example, an antibody capable of neutralizing both the 1918 and 2009
H1N1 influenza virus shows a 3-amino acid insertion in the heavy chain FR3 region;
crystallization showed that this insertion pushed the CDR2 loop into a useful
conformation for binding to hemagglutinin and was necessary for the antibody’s ability
to neutralize both strains (111–113). In another study, around 40% of surveyed broadlyneutralizing HIV antibodies (bnAbs) were found to have variable region indels, and in
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several cases the indels are either required for high-affinity binding or required for
subsequent affinity maturation of the bnAb lineage (114). In interesting recent work,
two patients from a malaria-endemic region in Kenya were found to express unusual
broadly-reactive antibodies against Plasmodium falciparum. Shockingly, these
antibodies contained not mere SHM-derived indels, but a 100-amino-acid insertion
between the V and D genes consisting of the entire collagen-binding domain of the
collagen receptor LAIR1. The mechanism for this last example is remains unknown authors found that the LAIR1 insert contained cryptic RSS site on either side, but both
copies of LAIR1 were still extant in the genomic DNA, which is inconsistent with RAG1’s
copy-paste mechanism (115). These results all suggest that indels are a particularly
powerful way of diversifying the antibody repertoire, with the potential of creating
reactivity to traditionally “difficult” antigens.
The combination of a “seed” VDJ recombination in the bone marrow and the
Darwinian pull of SHM in the periphery allows a single unique variable region in a pro-B
cell to give rise to an entire lineage of B cells after affinity maturation. Conceptually, a
particular B cell lineage can be discerned by its usage of shared V, D and J genes and
CDR3 sequence (with some mutation within the CDR3), with the highly diverse CDR3
sequence serving as a natural barcode propagated within said lineage. Therefore, the
antibody repertoire can be viewed as a series of disjoint lineages, each originating from
a single VDJ recombination event. This idea is reflected by high-throughput sequencing
experiments. In these data sets, binning all sequences by their assigned V and J gene
(which are presumed shared by any given lineage), then calculating the pairwise
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nearest-neighbor distance between CDR3 sequences within a given bin, gives a bimodal
distribution with a “near” peak corresponding to pairs of clonally-related sequences and
a more pronounced “far” peak corresponding to unrelated CDR3 (Figure 1-4) (116). The
task of sorting the repertoire into lineages, and the general difficulties of antibody
repertoire sequencing, will be discussed in the final section of this introduction.

1.1.4 Isotypes and Class-Switching
The constant region of an antibody is encoded by the C-terminal portions of the
heavy and light chain. The heavy chain constant region, in particular, is the sole
determinant of the antibody isotype, which determines the antibody’s effector function
(117). In humans, there are 5 antibody isotypes (IgM, IgD, IgG, IgA, and IgE), some of
which can be further divided into subclasses (IgG1 through IgG4, and IgA1 through
IgA2)(118). The 3’ end of the heavy chain locus contains exons corresponding to each of
these isotypes and subclasses, with a small repetitive switch region (S-region) and
intronic promoter (I-region) immediately 5’ of each exon (Figure 1-5) (119)(120).
Late-stage transitional B cells display both membrane-bound IgD and membranebound IgM through alternative splicing (121)(122)(123)(124)(125). Later, during affinity
maturation in the GC, AID (in addition to catalyzing SHM) can also catalyze class-switch
recombination (CSR) (126)(127)(128). In this process, the cytokine milieu generated by
TH cells and other cells within the GC epigenetically triggers transcription from a donor
and acceptor I-promoter in the IgH locus. The single-stranded DNA at the transcription
bubbles serves as a substrate for AID, inducing double-strand breaks due to a very high
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density of overlapping AID hotspot motifs. These lesions are subsequently repaired by
NHEJ between corresponding donor and accept S-regions, “looping out” the DNA
between them and forming a “switch circle” byproduct (129).
CSR is therefore a one-directional process – a B cell can switch from a 5’ exon
(like IgM) to a more 3’ one (like IgE), but the reverse is impossible. In particular, it is
worth noting that class-switching is often sequential, rather than direct from IgM. For
example, by cloning switch circles from ex vivo allergen-challenged human B cells, one
group showed that B cells can switch directly from IgM to IgE, or switch sequentially
from IgM to IgG4 to IgE (130). Similar results have been found in allergen-challenged
mice, with one study noting that a sequential switch was necessary to develop highaffinity IgE (131)(132). A high throughput sequencing study of IgE lineages from the
peripheral blood of 33 human subjects showed, based on shared somatic mutations
between sequences of different subclasses, that IgE-expressing B cells predominantly
arose through sequential switch, primarily from somatically-mutated clones in IgG1
(133). Another group proposed a model of sequential class-switching between IgG
subclasses (IgG3 > IgG1 > IgG2 > IgG4) over the course of an immune response, which is
supported by the presence of the requisite switch remnants in IgG1 and IgG2 B cells
(134)(135)(136). In a more expansive study, Stephen Quake’s group has recently
published a comprehensive landscape of human CSR by sequencing peripheral blood
cells from 11 pairs of healthy human twins and lineage tracing every variable region
sequence found. This work demonstrated that direct switching from IgM to downstream
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subclasses like IgA2, IgG4, and IgE is rare, and the majority of switches to these
subclasses pass through more upstream subclasses like IgG1 or IgA1 first (137).
Much as SHM diversifies the antigen-binding function of a given antibody, CSR
diversifies the effector function of each antibody (though with ten orders of magnitude
less diversity). A complete survey of each subclass and the signaling pathways leading to
their synthesis is the subject of ongoing research and is beyond the scope of this thesis;
however, those subclasses and cytokines most important for pemphigus pathogenesis
will be reviewed in section 1.2.

1.1.5 Autoreactivity and Tolerance
The vast capacity of the antibody repertoire to respond to nearly any antigen
over the course of an organism’s lifetime has a serious drawback – it has the capacity to
produce antibodies against self-antigens (138)(139). A seminal study showed that a
staggering 50 to 75% of immature B cells in the bone marrow react to cytoplasmic
and/or nuclear antigens in HEp-2 cell-line extracts (a standard assay for autoreactivity)
(140). There are several checkpoints in place to prevent these autoreactive clones from
propagating, both within the bone marrow (central tolerance) and in the periphery
(peripheral tolerance). These mechanisms are demonstrably impaired in several
autoimmune diseases, including multiple sclerosis (141), rheumatoid arthritis (142),
myasthenia gravis (143), Sjogren’s syndrome (144), and systemic lupus erythematosus
(SLE) (145), all of which demonstrate increased numbers of autoreactive B cell clones in
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the peripheral blood. The mechanisms of these checkpoints will be elucidated in this
section.
Upon expression of a pre-BCR at the pre-B cell stage, the nascent B cell is
challenged by a panoply of self-antigens within the bone marrow, beginning the process
of central tolerance (146). Subsequently, a high-affinity interaction between the preBCR and a self-antigen at this stage can trigger a number of different central tolerance
mechanisms, including receptor editing, anergy, and clonal deletion (147)(148)(149). In
receptor editing, a self-reactive pre-B cell arrests development, reactivates RAG1 and
RAG2, and attempts to abolish self-reactivity by re-rearranging the light chain locus
(150). Typically, the kappa locus is rearranged first, then the lambda
(151)(152)(153)(154). Subsequently, if the clone remains autoreactive, an analogous
process can occur at the heavy chain variable region, replacing the current VH gene with
a more upstream one (155)(156). This process can even occur serially, with multiple
upstream VH genes tested for autoreactivity (157). However, the details remain
controversial. Another study used a knock-in mouse model to show that that VH
replacement occurred before light-chain rearrangement, suggesting that VH
replacement isn’t involved in editing autoreactive antibodies (158). Furthermore, while
VH replacement typically results in lengthening of the CDR3 and leaves a “footprint” of
the replaced VH gene that can theoretically be detected algorithmically in sequencing
data (159)(160), other studies suggest many of these footprints may arise through other
mechanisms, including sequencing error and chance (161). Therefore, while VH
replacement is known to occur, both its overall frequency and its relevance to tolerance
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remains controversial. Chapter 3 of this thesis includes analysis of cloned antibodies for
autoreactivity, but for the above reasons it cannot reliably be determined which
receptor editing processes these clones have undergone within the bone marrow before
migration into the periphery.
If the B cell remains autoreactive after receptor editing, its differentiation is
arrested and it undergoes apoptosis after 2-3 days in a process called clonal deletion
(162)(163)(164). Deletion is the last central tolerance mechanism for eliminating a highaffinity autoreactive B cell before it enters the periphery; however, clones expressing
BCRs with low affinity can still escape. At this stage, those low-affinity clones that react
to abundant soluble antigen in the periphery can undergo tonic BCR stimulation in the
absence of co-stimulatory signals; this causes them to down-regulate surface IgM,
ignore mitogenic signals, and decreases their half-life, a state called anergy
(165)(166)(167)(168)(169). Anergic mature naïve B cells are excluded from the GC and
are unable to solicit T cell help; this prevents them from receiving critical survival signals
from the follicular niche and results in their death (170)(171)(172). The importance of
anergy in preventing autoimmunity can be seen in transgenic mice deficient for
inhibitory components of the BCR, like SHP-1 and SHIP-1; both of these are required for
anergy, and their knockout causes severe autoimmunity (173)(174)(175).
In healthy individuals, these central tolerance mechanisms manage to eliminate
most autoreactive B cells, but 5-20% of mature naïve B cells remain autoreactive (140).
At the level of GC and post-GC B cell development, there are a few more tolerance
mechanisms to consider. As previously stated, T cell help is required for the production
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of high-affinity antibodies (176), and more importantly a lack of T cell help in the GC
leads to B cell apoptosis (177)(178). T cells must cross their own tolerance checkpoints,
both within the thymus and the periphery; this decreases the chances that an escaping
autoreactive B cell and its cognate T cell both survive and meet in the GC (179)(180).
Affinity maturation in the GC can create autoreactive clones, some even
managing to differentiate into long-lived memory B cells (181)(182)(183)(184); however
apoptosis usually prevents newly-autoreactive B cells from escaping the GC (185). These
autoreactive B cells can undergo outright deletion in the periphery, as demonstrated in
several double-transgenic mouse experiments in which an antigen and B cell expressing
a cognate antigen-specific BCR are both expressed (186)(187). Subsequent experiments
showed that in these systems, deletion occurs due to the absence of T cell help (188).
Deletion isn’t the only fate for a new autoreactive clone, however. There’s some
evidence that receptor editing acts on autoreactive clones in the periphery (189),
though some mouse models suggest that heavy chain rearrangements in the periphery
actually improve autoantigen binding, rather than abolishing it (190)(191). In other
cases, further mutation and/or glycosylation of the variable region and further mutation
“redeemed” autoreactive clones (192)(193).
A simple analogy can be drawn between autoimmunity and cancer. Just as
cancer represents a failure of multiple checkpoints to prevent the unchecked cell
division of initially rare aberrant cells, autoimmunity is the result of a (sometimes quite
polyclonal) sub-population of autoreactive lymphocytes escaping multiple tolerance
mechanisms. Just as understanding the mechanisms of tumorigenesis has ushered in
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powerful targeted therapy for a variety of cancers, understanding the genesis of
autoreactive B cells has the potential to herald a new era in targeted therapy for
autoimmune disease. In chapter 3, we have combined antigen-specific screening and
high-throughput sequencing to trace the lineage of autoreactive B cells across several
subclasses, to better understand the origin and development of autoimmune disease. In
particular, we’re interested in tracing the B cell lineages responsible for the organspecific autoimmune disease pemphigus vulgaris (PV), which we describe in the next
section.

1.2 Pemphigus as a Model
1.2.1 Introduction
Pemphigus is a group of rare autoimmune diseases of the skin and mucous
membranes characterized by serum antibodies to cell adhesion proteins, causing
intraepidermal blistering (194)(195). The various subtypes of pemphigus are categorized
based on the adhesion proteins targeted by autoantibodies, and show different clinical
and histological presentations (Table 1-1). PV is the most common disease in this group,
occurring in 0.1-0.5 of every 100,000 people (196). In particular, the incidence of PV
seems to increase in populations with Middle Eastern, Jewish, or Mediterranean
ancestry. For example, in Hartford County, Connecticut, the incidence of PV in the
Jewish population was 3.2 per 100,000 people, while the overall adult population had an
incidence of 0.42 per 100,000. In Isfahan, central Iran, the incidence is even higher, at 5
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per 100,000 (197), though in the more southwestern city of Shiraz the incidence
dropped to 0.59 per 100,000 in another, suggesting some degree of geographic
variation (198). Among European populations, the UK seems to have a slight increase
over the continent, with a PV incidence of 0.7 per 100,000 (199), compared to 0.5-1.5
per million in Switzerland (200), France (201), Finland (202), and Germany (203).
Clinically, PV is characterized by suprabasal blistering of the oropharynx and a
positive ELISA against the cell adhesion protein desmoglein (Dsg) 3. Suprabasal blistering
of the skin can occur with the subsequent development of antibodies against a
homologous cell adhesion protein, Dsg1 (204)(205). This is reminiscent of another
disease in the group, pemphigus foliaceus, which is characterized by antibodies to Dsg1
and superficial skin blistering. The serum autoantibody profile of PV is used to
categorize it into its mucosal and mucocutaneous subtypes, the former expressing antiDsg3 antibodies, the latter expressing both anti-Dsg3 and anti-Dsg1. The reasons for this
tissue distribution will be made clear later in this section.
Pemphigus is a model autoantibody-mediated disease for a few reasons. First,
the autoantigens are well-characterized, with highly sensitive and specific ELISA assays
available for both Dsg3 and Dsg1. Second, antibodies have been shown to be both
necessary and sufficient for disease. For example, PV serum IgG causes blisters by
passive transfer into neonatal mice, while IgG from the serum of healthy subjects and
from PV serum with anti-Dsg3 antibodies removed by adsorption does not (206)(207).
Furthermore, monoclonal anti-Dsg3 antibodies cloned from PV patients can cause
blisters in neonatal mice and human skin (208)(209). These features make PV ideal for
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studying an antigen-specific autoantibody response, and for understanding the
evolution of an autoimmune repertoire.

1.2.2 Pathogenesis
The association between pemphigus vulgaris and autoantibodies was first
demonstrated in the 1960s, by immunofluorescence showing that patient sera binds in a
cell-surface pattern to human skin (210)(211). Almost three decades later, the
autoantigen was described by John Stanley’s group as a novel epithelial cadherin, later
cloned as Dsg3 (212)(213). Dsg3 mediates cell-cell adhesion as part of the desmosome,
which connects keratinocytes in stratified squamous epithelia. Within the desmosome,
desmogleins can undergo both homophilic interactions (214) and heterophilic
interactions (215)(216). Intracellularly, the C-terminal domain of desmogleins bind to a
complex of proteins including plakoglobin, plakophilin, and desmoplakin, which mediate
interactions with the keratin cytoskeleton (217). This allows the desmosome to resist
mechanical stress, such as rubbing of the skin; it is thus apropos that one of the clinical
signs of PV is “Nikolsky’s sign”, in which rubbing of normal skin forms a blister (218).
The extracellular domain of Dsg3 consists four extracellular cadherin-like
domains (EC1-EC4), which lie distal to a fifth extracellular domain dubbed EC5. The Nterminal EC1 and EC2 domains, which are the most and second-most distal to the cell
surface, respectively, have been shown to mediate cis (e.g. interactions between
proteins on the same cell) and trans interactions (interactions between proteins on
different cells) (219)(220). Because of this, binding of autoantibodies to these N20

terminal domains can directly disrupt trans interactions by disrupting desmosomal
assembly(221)(222) and/or causing internalization of Dsg3 into endosomes(223),
leading to blistering.
The N-terminal preference of PV autoantibodies is well-established, though
reactivity is not exclusive to that domain (224)(225). A longitudinal study of pemphigus
sera from 53 patients showed predominant reactivity with the EC1 domain at all stages
of disease, with decreasing percentages of sera showing reactivity as one moves to EC25 (226). A previous repertoire cloning experiment using phage display showed that
antibodies capable of causing a blister in neonatal mice by injection (“pathogenic”
antibodies) bound to the N-terminal 161 amino acids of Dsg3 (which covers EC1 and
part of EC2), while non-pathogenic antibodies preferentially bound to more C-terminal
domains (208). These studies all suggest that the autoantibodies most critical for PV
pathogenesis bind to the N-terminal EC domains of Dsg3. However, the role of
antibodies binding to C-terminal EC domains should not be overlooked. Injecting
multiple non-pathogenic antibodies together can cause a blister, suggesting that socalled non-pathogenic antibodies can work synergistically to have pathogenic activity
(227).
Dsg1 acts as a secondary target in PV, specifically appearing in its
mucocutaneous variant (204,205). The anti-Dsg1 and anti-Dsg3 ELISA have been
correlated to disease activity in skin and oral mucosa respectively (228), and anti-Dsg1
ELISA titer can predict skin relapse (229). These studies suggest that anti-Dsg1
antibodies are required for skin involvement in PV, and that anti-Dsg3 antibodies are
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insufficient to cause cutaneous blistering. This feature has been explained by the fact
that both Dsg3 and Dsg1 are expressed in the epidermis in an inverse fashion (Dsg3
being basal and Dsg1 superficial) (230)(231)(232), while Dsg3 is expressed much more
strongly than Dsg1 across all layers of the oral mucosa (233). These observations led to
the development of the desmoglein compensation hypothesis to explain pathogenesis.
The hypothesis states that in the skin, Dsg1 is capable of mediating adhesion when Dsg3
function is abrogated because it is expressed throughout the epidermis (including the
basal layer), while the expression of Dsg1 is both completely lacking in the basal layer
and significantly less than that of Dsg3 throughout the mucosa, making it unable to
maintain adhesion in the basal layer in the presence of anti-Dsg3 antibodies (234).
Evidence for this theory mainly comes from experiments in transgenic mice. One
experiment showed that antibodies to both Dsg1 and Dsg3 are required for blister
formation in neonatal wild-type mice, while Dsg3-null neonatal mice only required
antibodies to Dsg1 for blister formation (235). A transgenic mouse expressing Dsg3
ectopically in superficial layers of the skin is resistant to blistering when injected with
anti-Dsg1 serum (236). And finally, Dsg3(-/-) mice rescued with a Dsg1 transgene are
resistant to blistering upon injection with the anti-Dsg3 antibody AK23 (237).
From an antibody repertoire perspective, the fact that two homologous proteins
are targeted by the same disease, in a successive fashion, is very interesting. It may be
the case, for example that the anti-Dsg1 repertoire is entirely descended from anti-Dsg3
clones over the course of the autoimmune response – this would be a parsimonious
explanation to explain the transition from mucosal to mucocutaneous PV. Supporting
22

this idea is the fact that antibodies cross-reactive to Dsg3 and Dsg1 have been isolated
from PV patients (208). Alternately, the Dsg1 repertoire may arise completely
independently from the Dsg3 repertoire, despite the homology between the two. This is
supported by a study which showed that affinity purified anti-Dsg3 serum from PV
patients lacks reactivity to Dsg1 and vice versa (238), though it leaves open the
possibility that anti-Dsg1 and anti-Dsg3 antibodies share a lineage and somatic
mutations have modulated their reactivity. In chapter 3 of this thesis, we analyze both
anti-Dsg1 and anti-Dsg3 antibodies from a panel of patients through phage display as
part of a larger effort to define lineage relationships among autoreactive B cell clones in
PV.

1.2.3 The Features of Autoantibodies in Pemphigus Vulgaris
Like a handful of other autoimmune diseases, like anti-MuSK Myasthenia Gravis
(239) (240), thrombotic thrombocytopenia purpura (241), and others (242), PV shows an
IgG4 predominance during active disease. In particular, PV patients in active stages of
the disease predominantly show anti-Dsg3 IgG4 and less often anti-Dsg3 IgG1 (243).
Furthermore, autoantibodies show a 4-8 fold enrichment in IgG4 vs IgG1 sera by ELISA
(244). Other studies have demonstrated that healthy relatives of PV patients (rarely),
HLA-matched controls (rarely), and patients in remission can show anti-Dsg3 antibodies
of the IgG1 subclass, while those with active disease show both IgG1 and IgG4 anti-Dsg3
antibodies (245)(246). Another study suggested that during IVIG treatment, the levels of
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anti-Dsg IgG4 correlated better with clinical disease activity than anti-Dsg IgG1,
suggesting the IgG4 antibodies have a more critical role in mediating disease (247).
Structurally and functionally, the IgG4 subclass is unusual for several reasons.
IgG4 appears to arise in situations of chronic antigen stimulation, including in
beekeepers (248), chronic helminth infection (249)(250), and patients undergoing
allergen desensitization therapy (251). Because the constant region of IgG4 cannot fix
complement, only weakly binds to Fc receptors, and cannot form immune complexes,
IgG4 antibodies are believed to interfere with the binding of other antibody subclasses
to prevent overreaction of the immune system to a particular antigen
(252)(253)(254)(255). Also intriguing is the reciprocal relationship between IgG1 and
IgG4 over the course of an immune response. In beekeepers, repeated stimulation by
bee venom shifts the immune response to bee antigens from an IgG1 to an IgG4
predominant state (256). In a form of pemphigus foliaceus endemic to Brazil (fogo
selvagem), patients living in the endemic area in the preclinical stages have anti-Dsg1
IgG1, while patients with active disease show an IgG4 predominance (257). Taken
collectively, these observations suggest that anti-Dsg autoantibodies undergo a classswitch from IgG1 to IgG4 during active disease, potentially acquiring mutations that
cause epitope spreading or increase their affinity.
In addition to IgG1 and IgG4, the majority of PV patients have anti-Dsg IgA as
well (243)(258)(259). Note that there exists a rare clinical entity called IgA pemphigus,
which is characterized by a neutrophilic infiltrate and reactivity to desmocollins, but this
is considered a separate disease (see Table 1-1) and is therefore not relevant to our
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results. IgA is the subclass primary responsible for maintaining immunity on mucosal
surfaces as a first line of defense and to maintain homeostasis with normal flora
(260)(261). The mucosal immune system accomplishes this by using secretory IgA to
continuously sample antigens from the surface of the mucosa and modifying its
repertoire in response (262). There exist two IgA subclasses, IgA1 and IgA2; the former is
more prominent in the serum, while the latter is more common in the GI and GU tracts
(263)(264). Furthermore, because 25% of IgA secreting plasmablasts in the gut are
polyreactive, the mucosal immune repertoire may be a harbor of autoreactivity (265).
That fact, taken alongside the observation that PV often starts in the oral mucosa, led us
to hypothesize that IgA (specifically, IgA1) may contain clones cross-reactive to Dsg3
that eventually switch to IgG4 and cause disease.
The coexistence of four different antibody subclasses, which normally have
radically different functions in healthy subjects, all targeting 1-2 two autoantigens (Dsg1,
Dsg3, or both) makes PV an ideal model disease for studying the role of class switching
and antibody subclass in autoimmunity. An analysis of the lineage relationships between
anti-Dsg IgG1, IgG4, IgA1, and IgA2 can be found in chapter 3 of this thesis. We now
review a method of high-throughput B cell repertoire analysis using next-generation
sequencing, which was used in chapter 3 to shed light on these questions.
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1.3 Methods and Challenges of Antibody Repertoire Sequencing
1.3.1 Overview
The advent of high-throughput DNA and RNA sequencing has drastically changed
the way that genomes and transcriptomes are studied. By isolating all of the DNA or
RNA from a tissue sample (or even a single cell), scientists can gain unprecedented
insights into the genome or transcriptome at a much finer resolution than allowed by
previous microarray-based or Sanger-sequencing based efforts. Further improvements
to the technology, like ultra-deep sequencing and sequencing of targeted loci (266), has
allowed for detecting rare resistant viral sub-populations in HIV patients (267), rare
subclonal populations in cancer (268)(269), and previously unknown splice variants of
well-characterized genes (270).
High-throughput sequencing technology has also revolutionized the study of the
B cell repertoire (46). For example, experiments sequencing bulk DNA or RNA from
peripheral B cells have characterized the immune repertoire in healthy subjects
(271)(272)(273), assayed changes in repertoire during aging (274), found convergent
sequences across patients in infection (275), identified and lineage-traced broadlyneutralizing antibodies to HIV (276)(277), and studied the vaccination response
(278)(279)(280)(281)(282). Repertoire sequencing of autoimmune are not as common
yet, but experiments have shown exchange of pathogenic B cells between the periphery
and cerebrospinal fluid in multiple sclerosis (283)(284)(285), analyzed clonal expansions
over time in Sjogren’s syndrome (286), and demonstrated polyclonal nature of lupus
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flares (287). These studies have shed light on the fundamental mechanisms of
autoimmunity and have the potential to guide the future development of therapy.
The problems of sequencing the antibody repertoire are many-fold, and push the
limits of high-throughput sequencing technology in many ways. The most trivial of these
is the overall length of the VDJ locus; at ~450 bp, reliable sequencing of the entire
variable region reaches the upper limit of current sequencing read lengths, and
including an identifiable stub of the constant region (20-40 bp) and accessory barcode
sequences pushes this limit even further. Full length VDJ sequencing with acceptable
read numbers has been recently made possible in the last few years by Illumina’s MiSeq
2x300 bp paired-end platform, which outputs up to 25 million reads (288). Previously,
experiments have either sacrificed coverage using primers within the FWR2 (271) or
FWR3 (289) region, or sacrificed depth by using 454 Life Science’s GS FLX Titanium
platform, which touts read lengths up to 600-1000 bp but only obtains 106 reads per run
(290)(291).
Other issues in repertoire sequencing are largely due to the fact that repertoire
sizes push the 1011 range. Each and every one of those 100 billion sequences may be
important, in some broad sense, to any given antigen response. This has a few
implications. First, detection and reliable annotation of rare sequences is vital, much like
in ultra-deep sequencing; this is compounded by the fact that the B cell repertoire is
spread amongst the entire blood, lymphatic system, and potentially other tissues, AND
across several different B cell subtypes with differing functions. Furthermore, given the
clonal evolution of the repertoire by SHM, the ability to distinguish closely-related
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sequences from one another is critical to understanding the shape of a given antibody’s
lineage; this is especially difficult because amplification and sequencing error can
confound such efforts. Next, unlike the small handful of SNPs or mutations found in a
typical human or viral genome (which allows relatively painless annotation of
sequencing reads against a reference), the human VDJ locus contains a large number of
closely-related V, D and J genes, with many allelic variants, which are then further
mutated by SHM (sometimes on the order of 40 or greater mutations from germline
(292)), making VDJ assignment much more difficult. This is particularly difficult for the D
gene, which lies in the middle of the hypervariable CDR3 region. Next, assigning given
antibody sequences to clonal lineages is confounded by the above problem of VDJ
assignment, by sequencing and amplification error, and by the simple fact that
sequencing only captures the current VDJ sequence of a given B cell, and will not be able
interrogate its entire life story. Finally, the issue of assigning functional characteristics to
a given antibody sequence is currently impossible computationally, requiring additional
nontrivial experiments to be carried out alongside repertoire sequencing. Each of these
challenges will be addressed in the subsequent sections.

1.3.2 Sampling and Reproducibility
Humans have around 5 liters of blood, and a typical peripheral blood draw will
capture only 0.1-1% of this. In addition, only 2% of the 1011 B cells in the average human
are circulating at any given time, with the rest sequestered in bone marrow, spleen,
lymph nodes, mucosal tissue, etc (46). Both of these facts make sampling the overall
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repertoire challenging. Early experiments performed on Danio rerio managed to evade
both of these constraints by simply snap-freezing, lysing, and extracting the RNA from
entire fish, making all 3 x 105 B cells accessible to sequencing (293)(294). Repertoire
sequencing experiments on mice also manage to avoid these constraints, because in
addition to having a thousand-fold smaller B cell repertoire than humans, the lymphoid
tissue of mice is more easily obtained by surgery (295)(296).
Because of these technical, practical, and ethical constraints, repertoire analysis
in humans will necessarily be limited by sample. These limits can be assessed using
biological and technical replicates for estimating the overall depth of sampling (47,296).
Data from biological replicates (e.g. multiple blood or tissue samples from the same
subject) quantifies the amount of biological undersampling, while technical replicates
(e.g. multiple PCR or sequencing experiments on the same biological sample) quantifies
the sufficiency of sequencing depth. This kind of replicate data is particularly useful for
capture-recapture analysis, in which the degree of overlap (either in terms of lineages or
individual sequences) between two samples is used to estimate the amount of the total
population captured; this is similar to the mark-and-recapture analysis used to estimate
populations in ecology (291)(293)(297). A popular unbiased statistic used for this
purpose is Chapman’s modification of the Lincoln-Petersen estimator, which uses the
overlap between a pair of samples from a population to calculate the total population
(297)(298).
A key assumption of capture-recapture methods is that each individual member
of the population is equally likely to be “caught” by sampling (299); this assumption is
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usually untenable, since lineage sizes and sequence copy numbers within the repertoire
are not uniform, at either the RNA or DNA level. In other words, a B cell clone with
multiple copies is more likely to be “trap happy”, e.g. more likely to be sampled multiple
times, artificially inflating the overlap between samples. Methods to decrease the
effects of trap heterogeneity are the subject of ongoing research, though none have yet
been applied to antibody repertoire sequencing (300)(301).
Another ecology-inspired method, less subject to heterogeneity bias, is
abundance-based rarefaction analysis, in which subsampling the reads from a given
sample is used to create an accumulation curve (296)(302) . Some measure of diversity
(e.g. number of unique sequences or lineages) in each subsample is plotted against the
number of reads in the subsample, with the hope that the subsequent curve shows
saturation as the number of subsampled reads approaches the actual number of reads.
As the number of reads increases, the curves tend to quickly rise and plateau, as the
common species (equivalent to large lineages) are quickly added to the curve, leaving
only rare species (smaller lineages) to be found.
Recently, this analysis has extended this kind of analysis to include extrapolation
and nonparametric asymptotic estimation of diversity, allowing the construction of
smooth rarefaction curves using both interpolation and extrapolation via the Chao
method (303)(304). The nonparametric nature of this analysis means its results are not
reliant on the distribution of species in the population, unlike the capture-recapture
estimation outlined above. The mathematical details are outside the scope of this
thesis, however a thought experiment is illustrative. Imagine a sample containing one
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thousand different lineages, each of them with only one read (singletons). Compare that
with a sample containing 25 different lineages, 20 of which have 100 or more reads and
5 of which have a single read. It is easy to see why the second sample is closer to
saturation than the first. If our sample predominantly consists of singletons, it suggests
that collecting a larger sample will easily find new species. By contrast, if singletons are
only a small proportion of the sample, further sampling will probably not find many new
species. The Chao method takes the proportion of singletons, two-read species, etc up
to 10-read species into account, using this to infer the number of unfound species for
extrapolation.
A drawback of the Chao method is that it is exquisitely sensitive to the presence
of singleton lineages (i.e. lineages with only one sequencing read assigned to them); this
is a particular concern because sequencing error often inflates the number of lowfrequency members in a sample (305)(306). Some non-statistical methods of removing
erroneous sequences are discussed in the next section; however, for the purposes of
diversity estimation, we can also statistically deflate the number of low-frequency
counts according to some expected distribution. Sampling analysis in chapter 3 employs
a method that uses Good-Turing frequency estimation (307)(308) to deflate the
singleton count by generating an “expected” singleton count from the number of
doubletons, tripletons, and quadrupletons (lineages containing 2, 3, and 4 reads,
respectively), thus giving a more accurate estimation of diversity (309). However, it is
worth noting that sequencing error inflates all low-frequency counts, including
doubletons, tripletons, and quadrupletons, suggesting that even with statistical
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correction we may be inflating our lineage counts slightly. Future developments in the
field, including better statistical methods and technical improvements in sequencing,
will lead to more accurate estimation of diversity and coverage in high-throughput
sequencing datasets.
The effects of tissue choice on sampling are less well-known, as studies of B cell
repertoires from non-blood tissues in humans has just begun. One group has conducted
a repertoire sequencing study using RNA samples from peripheral blood, bone marrow,
small intestine, lung, stomach, lymph node, tonsil, spleen, and thymus, discovering that
the mucosal repertoire was quite different than that of the peripheral blood and
lymphoid tissues in terms of VDJ use, CDR3 length, and somatic mutation frequency
(310). Another group has also conducted B cell repertoire sequencing from both blood
and cerebrospinal fluid in patients with multiple sclerosis, showing extensive exchange
of B cells between the two compartments (311).
Because previous repertoire cloning studies in PV have used peripheral blood,
managing to find several anti-Dsg clones (208), and because of the difficulty of sampling
other compartments, the studies in chapter 3 are restricted to blood, and therefore may
miss relevant B cell diversification events in the mucosa, spleen, or other
compartments. It is entirely feasible, for example, that skin-draining lymph nodes in
pemphigus contain distinct repertoire of anti-Dsg antibodies. Further studies comparing
different tissue-specific repertoires in PV may shed light on their role in disease states.
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1.3.3 Error Correction
In any high-throughput sequencing experiment, there are two main sources of
mutational error – from amplification, and from sequencing. The Illumina MiSeq
platform used in this thesis is known to be prone to substitution error, especially in GCrich regions, on the order of 1-2 bases per 1000 nucleotides (312)(313). While this error
rate may be sufficient for simple RNA-seq expression studies, it is unfortunately on the
order of the mutation rate for SHM (which is approximately 1 in 1000 bp per cell
division) (102). This is compounded by the fact that the mutation rate for the
commonly-used Q5 Hi-Fidelity polymerase is around 1 in 10,000 bp (314).
Computational and experimental methods of dealing with this error will be discussed in
this section.
A common method of eliminating PCR error in diverse sequence sets (e.g
bacterial metagenomics studies) is full-length clustering using an algorithm like
USEARCH, which sorts all sequences by their copy number, using the most abundant
sequences as centroids to agglomerate less-abundant sequences within a certain
number of mutations (315). USEARCH has been incorporated into the SONAR pipeline
(316), and into our custom pipeline. A conceptually similar homology-based centroid
clustering approach, called AbCorrect, has also been developed (317). More advanced
clustering schemes incorporating multiple alignment to a VDJ reference and
incorporating quality scores also exist (318)(319).
Unfortunately, many clustering schemes cannot distinguish between a PCRinduced error and a rare somatically mutated variant within the clustering radius. A
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clever graph-theoretic approach developed as part of the IgRepertoireConstructor
package attempts to address this problem (320). First, each unique sequence is assigned
to a vertex, and all vertices within a certain mutational distance are connected by an
edge. Putative “real” sequences correspond to well-connected components called
corrupted cliques within the graph; unfortunately, finding corrupted cliques is a
computationally difficult (NP-hard (321)) problem. Within each clique, edges connecting
sequences that differ at an SHM hotspot are treated distinctly from other mutations, in
order to separate out “real” antibodies within a larger cluster from PCR errors. This
algorithm, while clever, is also rather slow, though improvements published in 2016 are
touted to decrease runtime from days to minutes for a typical dataset (322).
A widely-adopted experimental method to reduce error and the effects of
amplification bias in transcriptomics is the incorporation of unique molecular identifiers
(UMIs), short stretches of degenerate nucleotides, to cDNA during reverse transcription
(323–325). Because the UMI is incorporated before subsequent amplification, all
mutated “descendants” of that molecule erroneously created by PCR and sequencing
will inherit the same UMI. Thus, clustering all reads sharing a UMI can not only be used
to eliminate mutations, it can also be used to smooth over PCR-induced amplification
biases that prevent accurate quantitation. Several recently-developed experimental
pipelines, including MAF (326) and MIGEC (327)(328), incorporate UMIs into antibody
repertoire sequencing to achieve significant decreases in error and accurate
quantitation.
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However, UMIs are not a panacea, and require appropriate experimental design
for proper use. First, it is important to select a UMI scheme with sufficient diversity to
uniquely tag every single mRNA molecule in a given sample (329)(330)(331). Insufficient
UMI diversity will cluster together completely unrelated sequences, resulting in the
elimination of the less-abundant one in the cluster. An easy method to increase UMI
diversity is simply lengthening the UMI; however, this also makes the UMI more prone
to mutations, which artificially increase the diversity of the sample (47)(332)(333).
Methods of correcting mutations within the UMI include using histograms to find
nearest neighbor distances between UMI variants and treating rarer variants as errors
(334), and network-based methods (335). A final issue, which is especially noticeable
when searching for rare variants, is the fact that the initial UMI tagging during reverse
transcription may lack perfect efficiency; in some extreme cases, only 0.2% of the initial
templates were successfully tagged (332)(333). No well-validated method for
overcoming this bias has been implemented in antibody repertoire sequencing, though
a recently-developed scheme in which single nucleic acid templates are encased in
picoliter droplets and individually barcoded could theoretically eliminate competition
between templates (336).
The use of UMIs has been widely adopted in repertoire sequencing, though
some issues remain. Improved quantification and error correction comes at the
potential of significantly decreased sequencing depth. Experiments in chapter 3 eschew
the use of UMIs, partly because of our focus on deeply sampling the rare IgG4 subclass
(necessitating high inputs of RNA), reliably separating the IgG4 subclass from the others
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(necessitating an additional amplification step), and our desire to use phage display
libraries for antigen-specific selection. For fine lineage analysis, we instead used
USEARCH and a minimum read cutoff to filter out likely erroneous sequences, using a
monoclonal amplicon subject to the same amplification steps to validate our method.

1.3.4 VDJ Assignment and Lineage Analysis
Because the IgH variable locus is highly polymorphic and contains several similar
families of sequences, the assignment of germline VDJ genes to a transcript is not trivial,
even before taking SHM and the existence of N and P nucleotides into account. The
original zebrafish repertoire sequencing experiment had a 99.6% V-gene assignment
rate (293); with a more complex, mutated repertoire, this is bound to be worse. This is
made even more difficult because several V gene alleles remain undiscovered (337). The
simplest VDJ assignment algorithms are the alignment-based IgBlast (338) and IMGTHighVquest (339), which are well-established tools with high throughput and simple
web interfaces. Some alignment algorithms are particularly focused on the CDR3 region
and purport to improve D gene assignment; examples include Ab-origin (340), which has
a tweaked scoring scheme, and Joinsolver (341,342), which used Monte Carlo
simulations to do the same. More advanced algorithms based on Hidden Markov
Models (HMMs) include the SODA2 (343) and iHMMuneAlign (344), both of which use a
negative binomial distribution for transition states, and the more complex multi-HMM
based partis (345), which uses empirical distributions of VDJ recombination to better fit
the data.
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VDJ assignment is particularly important for analyzing lineages of related
antibodies arising from a single naïve B cell clone (sometimes called a “clonotype”).
Many pipelines (e.g. Change-O (116) and ClonalRelate (346)) assign sequences to
lineages by first partitioning by assigned V gene, J gene, and CDR3 length, then
separating out related sequences using a CDR3 distance cutoff between members of the
lineage based on statistics. Alternately, a shared somatic mutation cutoff along the
entire variable region can be used instead of CDR3 distance after partitioning, for
example only allowing variable regions that share five mutations from their calculated
germline sequence to share a lineage (296)(347) . Either approach would naturally
separate related sequences mis-assigned to different V or J genes; this is of particular
concern in sets of highly mutated sequences, like HIV bnAbs. One method to overcome
this is to use phylogenetics on a database of V and J genes to improve the initial
assignment, such as in IgSCUEAL (348). An alternative method is to assign sequences to
lineages without first assigning V and J genes. This can be done, for example, by directly
calculating a pairwise distance matrix between sequences (349), though this can
become computationally intensive for large number of sequences.
In chapter 3, novel approaches are employed to deal with both VDJ assignment
errors and clonal assignment. After performing germline and CDR3 assignments using
IMGT-HighVquest, all sequences in the dataset are binned by V gene, J gene, and CDR3
length. However, in order to assign reads to lineages with more confidence, we chose to
calculate the nearest-neighbor CDR3 nucleotide identity between different patients,
rather than within the same patient, to set a per-patient cutoff. Because sequences
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between patients should not be related, this can be used to bound the probability that
any CDR3 similarity cutoff would erroneously cluster two unrelated sequences into a
single lineage. The cutoffs for 99% confidence under this framework varied between
80.6% and 86.1%, quite similar to previously used values based on within-patient
analysis. Secondly, to mitigate the effects of V- and J-gene mis-assignment and
sequencing error, all clusters were subsequently sorted into superclusters solely based
on CDR3 similarity, using the same per-patient cutoffs. Within each supercluster,
clusters were ranked by read count, then only the top-ranked clusters within each
supercluster were used for subclass connectivity analysis and lineage analysis through
phylogenetic trees. This eliminated only ~10% of the total reads in each sample, but also
eliminated anywhere from one-half to five-sixths of all clusters, significantly
ameliorating the effects of sequencing error and germline mis-assignment on the
construction of lineages.
Once sequences have been sorted into lineages, the next task is to draw a
lineage tree using those sequences, which can offer insight into the temporal structure
and evolution of the antibody response. Many tools from evolutionary biology can be
adapted for this purpose, including maximum parsimony and maximum likelihood
algorithms (350). Briefly, a maximum parsimony algorithm considers a set of sequences,
and arranges them in a tree to minimize the total number of mutations (351), while a
maximum likelihood method takes different site-specific mutation rates into account
when drawing the tree, creating the most likely tree based on a calculated prior
probability distribution (352). Both of these methods have been applied to antibody
38

sequences (116)(284)(353). Work in this field is ongoing, with more research needed to
validate these methods and compare them against each other in immunological
sequence datasets (47).
In order to ensure the robustness of our conclusions, we used both maximum
parsimony (through ChangeO and PHYLIP’s dnapars program) and maximum likelihood
(through PASTA) algorithms to analyze anti-Dsg lineages containing both IgG1 and IgG4
sequences. Both methods generated trees with similar topologies, suggesting our
conclusions were robust to the phylogenetic method selected. Additionally, ChangeO’s
particular implementation of maximum parsimony also calculates the sequence of
inferred ancestors in the tree. This was particularly useful for determining the sequence
of the most recent common ancestor (MRCA) in each lineage; these could then be
synthesized (along with several other sequences in each tree) and tested by ELISA in
order to trace the onset and development of anti-Dsg reactivity.

1.3.5 Conclusion
It is clear that high-throughput sequencing can offer many insights into the antibody
repertoire. In particular, the ability to infer lineage relationships within the antibody
repertoire is intriguing, and is particularly relevant to the task of tracing the lineage of
anti-Dsg B cells belonging to different antibody subclasses. By sequencing subclassspecific amplicons and sorting them into cross-subclass lineages, one can map the global
relationship between IgA1, IgA2, IgG1, and IgG4. Furthermore, by combining this data
with phage display as a means to isolate Dsg-specific heavy chains, we have the ability
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to not only determine which sequences within the repertoire are autoreactive, but how
they arose and how they relate to each other across antibody subclasses. The results of
this repertoire sequencing study can be found in chapter 3.

1.4 Experimental Approach
1.4.1 Rationale
The focus of this thesis is to analyze the role of antibody subclass in the
pathogenesis of PV. Because previous studies have shown that variable regions alone,
either in Fab or single-chain variable fragment (scFv) form, are sufficient to cause
blistering in model systems, there are broadly speaking two ways in which the subclass
of an anti-Dsg antibody could be relevant to its role in pathogenesis. First, the subclass
could be directly involved in the binding activity of the antibody, by altering the binding
properties of the variable region. For example, a given anti-Dsg variable region could
have different binding affinity when attached to either IgG1 or IgG4, due solely to
structural differences in the constant region. The influence of the constant region on
antibody affinity and pathogenicity is the subject of experiments found in chapter 2.
Alternatively, the subclass of an antibody could simply reflect the developmental
history of the B cell synthesizing it. In other words, the structure or effector function of
the heavy chain constant region that determines subclass may itself not be particularly
important, but mapping the pathway leading autoreactive antibodies to occupy a
particular antibody subclass may shed light on the processes involved in PV
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pathogenesis. We can infer these pathways by analyzing clonal overlaps between antiDsg variable regions of different subclasses, tracing the lineages of autoreactive B cells
as they switch from one subclass to another. In this way, analyzing subclass-specific B
cell repertoires in PV will shed light on the mechanisms leading to the development of
anti-Dsg antibodies across subclasses, and elucidate the contribution of class-switching
to the pathogenesis of PV and antibody-mediated autoimmunity in general.
Experiments tracing subclass-specific B cell lineages in a panel of PV patients are found
in chapter 3.

1.4.2 Chapter 2
Experiments conducted in chapter 2 of this thesis analyze the possibility that
epitope characteristics and of anti-Dsg antibodies are affected by subclass. While the
variable region of an antibody is thought to be responsible for most of its binding
properties, some studies have shown a role for the constant region in modulating
reactivity (354). The anti-HIV bNAb 2F5 shows increased affinity and the ability to bind a
new epitope when expressed as IgA2 than as IgG1 (355). Another group found that the
catalytic DNA cleavage activity (356) and renal pathogenicity (357)(358) of the murine
anti-nuclear antibody PL9-11 is influenced by its isotype. These findings raise the
possibility that anti-Dsg3 IgG1 and IgG4 antibodies are closely related, and that classswitching from IgG1 to IgG4 is all that’s needed to cause the same variable region to
become pathogenic.
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In chapter 2, we clone three anti-Dsg antibody variable regions previously
isolated from PV patients onto IgG1 and IgG4 backbones. Then, we compare them
pairwise for epitope preferences, ELISA and IIF titer, blistering ability on skin explants,
and ability to internalize Dsg on the surface of keratinocytes. By cloning the same
variable regions onto two different constant regions, we show that an antibody’s
affinity, pathogenicity, and ability to trigger Dsg internalization of an antibody is not
significantly modulated by whether it expresses an IgG1 or IgG4 constant region.

1.4.3 Chapter 3
Experiments conducted in chapter 3 trace anti-Dsg B cells across the IgG1, IgG4,
IgA1, and IgA2 subclasses in the peripheral B cell repertoire of a panel of four PV
patients. These experiments are conducted using RNA from peripheral blood
mononuclear cells (PBMC) isolated from 50 mL of peripheral blood from each patient.
This quantity of blood represents approximately 1% of the peripheral repertoire (given
that humans harbor approximately 5L of blood) and 0.02% of the total B cell repertoire
(given that 2% of the B cell repertoire is in the periphery (46)). The RNA is used to
generate subclass-specific amplicons using a 3’ primer binding to the hinge of the
constant region and 5’ primers binding to the beginning of FWR1 on the variable region.
These amplicons are then used to create sequencing libraries for the Illumina MiSeq
2x300 bp paired-end sequencing protocol, and to create subclass-specific phage display
libraries, which are subsequently panned against both Dsg1 and Dsg3 in order to isolate
Dsg-reactive antibodies from each patient-subclass pair. Anti-Dsg clones isolated by
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panning were subject to both ELISA and indirect immunofluorescence to confirm
binding to desmoglein and recapitulation of the PV cell-surface binding phenotype,
respectively.
Antibody phage display is a method of isolating antigen-specific antibodies by
cloning heavy and light chains into a phagemid vector, which allows the antibody to be
expressed as either a scFv or Fab on the surface of filamentous bacteriophage. A library
of phage can then be subject to several rounds of selection and amplification against an
immobilized antigen, isolating clones reactive to the antigen of interest (359). The
technique is particularly useful to this study because it has the power to screen up to
109 different transformants in a single library, giving much higher throughput than single
B cell cloning or heterohybridoma methods and conferring the power to find and
characterize both rare and common clones. Phage display has been used to clone
autoantibodies in acquired thrombotic thrombocytopenia purpura (360), idiopathic
thrombocytopenia purpura (361), pemphigus foliaceus (362), and systemic lupus
erythematosus (363)(364).
Previous phage display experiments in PV, in which all IgG subclasses were
cloned into single libraries (making IgG1 and IgG4 indistinguishable), have been used to
show that VH gene usage in anti-Dsg3 antibodies is highly restricted (208,365–367).
Another set of phage-display derived pathogenic antibodies demonstrated a D/E-X-X-XW motif in the heavy chain CDR3, suggesting that shared heavy chain sequence
characteristics may be used to distinguish and target autoantibodies (209,368). Because
of this restriction, and because of the fact that heavy chains are more diverse, are more
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important for antigen binding, and generate traceable lineages, most of our analyses
focus on heavy chain repertoires in PV.
However, it is worth noting a key drawback of phage display is the random
pairing of heavy and light chains in the library, since each is amplified separately from
total RNA and PCR-overlapped into a single insert. Because of this, information about
the actual heavy-light pairing is lost during cloning, creating the possibility that either a
reactive heavy chain does not find a suitable light chain to pair with, or that a nonreactive heavy chain pairs with a light chain that makes it reactive. There are a few
reasons to suggest that this is less of a problem than it initially appears. As would be
suggested from its diversity, the heavy chain CDR3 has been experimentally
demonstrated to be the main determinant of antibody specificity, with the light chain
being less important. In one study, surface plasmon resonance assays showed that the
heavy chain of an anti-thyroglobulin antibody recognizes its epitope in the complete
absence of a light chain, showing the primacy of heavy chain interactions for binding
(369). The primacy of the heavy chain was also shown by another group creating phage
display libraries from a pool of several heavy chains with synthetic CDR3 regions and a
single invariant light chain, and demonstrating that they harbor clones reactive against
several haptens and protein antigens (370)(371). Another group showed that transgenic
mice expressing a single heavy chain V gene, but the full complement of D and J genes,
developed high-affinity antibodies in response to several different injected antigens,
despite restricted combinatorial diversity, showing that the combinatorial and junctional
diversity within the heavy chain CDR3 was sufficient to generate such responses (372).
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By tracing the B cell repertoire across multiple subclasses, we were able to
determine that the IgG4 anti-Dsg lineages tended to be solitary, containing only IgG4
clones. Furthermore, when IgG1 and IgG4 shared a lineage, they often diverged from a
common ancestor early, rather than showing a direct switch between IgG1 and IgG4.
This is in contrast to IgA1 and IgA2, which commonly showed IgA1 to IgA2 direct-switch
relationships. We also found that IgA subclasses tended to switch directly from IgG
subclasses, rather than the other way around, suggesting that IgA may serve as a
disease-modifying factor in PV, rather than serving as a source of anti-Dsg IgG clones.
These results and analysis can be found in chapter 3.
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1.5 Figures and Tables
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Figure 1-1. Diagram of VDJ Recombination at the Human Heavy Chain Locus. A D and J
segment are randomly selected then joined together by RAG1/2, with nucleotides at the
junction (in red) added by TdT or removed by exonuclease chewback. A similar process then
occurs with a randomly selected V and the already-joined DJ segment, creating the final VDJ
variable chain.
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Figure 1-2. Diagram of VJ Recombination at the Human (A) Kappa and (B) Lambda Locus. A V
and J segment are randomly selected then joined together by RAG1/2, with nucleotides at the
junction (in red) added by TdT or removed by exonuclease chewback. In the Kappa locus, there’s
a single constant region exon on the 3’ end of the locus, while in the Lambda locus, there’s a
constant region exon immediately 3’ of each J gene.
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Figure 1-3. CDRs and FWRs are Interspersed among the V, D and J Genes of the Variable Heavy
Chain. In particular, the V gene contributes to both the CDR1 and CDR2, but all three genes
contribute to the CDR3. Red indicates junctional nucleotides added during VDJ recombination
(see Figure 1-1).
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Figure 1-4. Clonality Plot. 2000 sequences obtained by deep sequencing from PV8 were
randomly selected. After binning sequencing by V, J and CDR3 length, the nearest-neighbor
hamming distance between CDR3s are measured, in order to separate clonally related
sequences from unrelated sequences. The red arrow indicates the minimum in the histogram,
which would be used to set a CDR3 similarity cutoff for clonality. Distance = (Hamming distance,
or # of substitutions)/(CDR3 Length)
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Figure 1-5. Diagram of Human IgH Constant Region Locus. Each exon encodes a different heavy
chain constant region, as indicated. Circles immediately adjacent to each exon represents switch
regions, which serve as substrates for AID to initiate class switching. Note that class switching
occurs from left to right, so for example, an IgM to IgG4 switch is possible, but not vice versa, as
the intervening DNA is excised. Note that as displayed, there is no switch region in front of IgD,
consistent with its co-expression with IgM. However, a small proportion of B cells do switch to
expressing solely IgD, made possible due to the presence of a rudimentary switch region
between IgM and IgD (121,373).

Adapted from: Figure 4a of
Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et
al. Human memory B cells originate from three distinct germinal center-dependent and independent maturation pathways. Blood. 2011 Aug 25;118(8):2150–8.
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CHAPTER 2:

Swapping the Constant Region in Pathogenic IgG1 and IgG4 Autoantibodies in Pemphigus
Vulgaris Does Not Alter Blister-Inducing Ability or Epitope Preference

2.1 Abstract
Pemphigus vulgaris (PV) is characterized by IgG1 and IgG4 autoantibodies to desmoglein
3 (Dsg3), causing suprabasal blistering of skin and mucous membranes. Both IgG1 and IgG4
appear during active disease, whereas IgG1 can be associated with remittent disease; this
partially reciprocal relationship, and the relative positions of heavy chain constant region loci,
suggests the possibility that IgG1 clones switch to IgG4 clones over the course of disease. To
investigate the possible role of the IgG constant region on modulating blister-inducing ability
and binding properties in anti-Dsg3 autoantibodies, we tested whether three pathogenic PV
mAbs from three different patients demonstrate differences in antigen affinity, epitope
specificity, or blister-inducing ability in model systems when expressed as IgG1 or IgG4. F706
anti-Dsg3 IgG4 and F779 anti-Dsg3 IgG1, previously isolated as heterohybridomas, and Px43, a
monovalent cross-reactive anti-Dsg3/Dsg1 IgG antibody isolated by phage display, were
subcloned to obtain paired sets of IgG1 and IgG4 mAbs. Using ELISA and cell surface staining
assays, F706 and F779 demonstrated similar antigen binding affinities of IgG1 and IgG4. Px43
showed 3 to 8-fold higher affinity of IgG4 versus IgG1 by ELISA, but identical binding affinities to
human skin, perhaps due to targeting of a quaternary epitope best displayed in tissues. All 3
monoclonal antibody (mAb) pairs targeted the same extracellular cadherin domain on Dsg3,
caused Dsg3 internalization in primary human keratinocytes, and caused suprabasal blisters in
human skin at comparable doses. This work suggests that switching the IgG1 and IgG4
subclasses of pathogenic PV mAbs does not directly affect their antigen binding or pathogenic
properties.
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2.2 Introduction
Pemphigus vulgaris is a potentially life threatening autoimmune blistering disease
caused by IgG autoantibodies against Dsg3 +/- Dsg1, desmosomal adhesion proteins of
keratinocytes (374). In mucosal PV, autoantibodies react against Dsg3, which is the major Dsg
isoform expressed in basal keratinocytes of the mucosa, leading to suprabasal blistering. In
mucocutaneous PV, autoantibodies target both Dsg3 and Dsg1, causing suprabasal blisters in
both mucosa and skin. Antibody cloning studies from PV patients have shown that a single mAb
can bind Dsg3 only, or both Dsg3 and Dsg1 (375)(208)(376). Epitope mapping studies indicate
that autoantibodies from pemphigus patients with active disease bind near the N-terminus of
Dsg3, where residues important for cis- and trans-adhesive interactions reside (225,376).
Although monovalent anti-Dsg antibody variable region fragments are sufficient to
cause skin blisters in the absence of the constant region (377), preferential use of IgG subclasses
has been identified in pemphigus patients. In active disease, anti-Dsg3 IgG4 autoantibodies are
predominantly found in PV sera, followed by IgG1, and occasionally IgG2 and IgG3 (243). In
contrast, patients in remission and sometimes healthy relatives of PV patients can demonstrate
anti-Dsg3 IgG1 (245,378). These early studies in the field suggested that IgG4 antibodies could
induce blisters but IgG1 antibodies could not. Subsequently, heterohybridomas produced from
PV patients have shown that pathogenic anti-Dsg3 mAb can derive from either the IgG1 or IgG4
subclass (367,375,376).
While it is clear that IgG4 is associated with active disease in PV, it is unknown whether
the same variable region of a pathogenic IgG4 mAb, expressed on an IgG1 constant region,
directly affects antibody function, through altering antibody affinity, epitope binding
characteristics, Dsg3 internalization, or blister-inducing ability. In the study presented here, we
selected three representative pathogenic PV mAbs cloned from 3 different PV patients: F706, an
53

anti-Dsg3 IgG4 isolated by heterohybridoma, F779, an anti-Dsg3 IgG1 isolated by
heterohybridoma, and Px43, an anti-Dsg3/Dsg1 monovalent IgG antibody of unknown subclass
isolated by phage display, and generated pairs of recombinant IgG1 and IgG4 antibodies
expressing identical variable regions. To determine whether the constant region modulates
affinity, epitope specificity, or pathogenic properties of anti-Dsg variable regions, we compare
these antibodies pairwise by ELISA titer, IIF titer, pathogenicity in skin explants, and Dsg
internalization ability.

2.3 Materials and Methods
2.3.1 Human Anti-Dsg3 mAb Cloning
The three patients from whom the antibodies were cloned had active, extensive PV
involving both mucosa and skin. The diagnosis of PV was confirmed by histology and
immunofluorescence. All patients were untreated at the time of blood draw. F706 IgG4 and
F779 IgG1 were isolated from two different patients by heterohybridoma as described
(367,379). Px43 was isolated from a third PV patient by phage display (208).

2.3.2 Recombinant mAb Subcloning, Expression, and Purification
Primers were designed to amplify the F706 and F779 heavy chain (HC) and light chain
(LC) variable domains for subcloning into the pHC or pLC vector (380,381). Primers are designed
to bind to the 5’ UTR (leader) and the 3’ end of the JH-gene, while light chain primers bind to the
5’ UTR (leader) and the constant region. Primer sequences were as follows (restriction sites
underlined):
5’ F706HC NheI: TCTAGCTAGCCGCCACCATGGACTGGACCTGGAGGGTCTT
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3’ F706HC HindIII: TAGGGCAAGCTTGCTGAGGAGACGGTGACCAGG
5’ F706LC NheI: TCTAGCTAGCCGCCACCATGAGGCTCCTTGCTCAGCT
3’ F706LC NotI: TAGGGCGCGGCCGCAGTTCGTTTGATTTCCACCTT
5’ F779HC NheI: TCTAGCTAGCCGCCACCATGGACTGGACCTGGAGGGTCTT
3’ F779HC HindIII: TAGGGCAAGCTTGCTGAGGAGACGGTGACCAGG
5’ F779LC NheI: TCTAGCTAGCCGCCACCATGAGGCTCCTTGCTCAGCT
3’ F779LC NotI: TAGGGCGCGGCCGCAGTTCGTTTGATCTCCAGCTT

Recombinant DNA plasmids encoding cognate heavy and light chains were cotransfected into CHO-K1 cell lines using Lipofectamine 2000 (Invitrogen, Grand Island, NY), with
IgG1 and IgG4 heavy chains cloned into separate lines. Transfectants were cloned by limiting
dilution in selective media (RPMI containing 10% fetal bovine serum, 10µg/mL puromycin,
800µg/mL G418) to establish permanent cell lines. The antibody supernatant was collected and
purified by affinity chromatography on a Sepharose protein G column with acid glycine elution.
F71 IgG1 mAb (targeting an unknown antigen) and anti-HIV b12 IgG4 mAb were used as isotype
antibody controls for some in vitro experiments.
Px43 IgG1 and IgG4 were cloned as previously described (368)(382). Briefly, heavy and
light chains were individually amplified from Px43 scFv in the pComb3X vector, then cloned into
the PIGG vector (383). The heavy chain was amplified to introduce a SacI cloning site on the 5’
end and an ApaI cloning site on the 3’ end (the endogenous ApaI site in the CH region of IgG).
After PCR purification using the Qiaquick PCR purification kit (Qiagen, Valencia, CA), digestion
using SacI and ApaI (New England BioLabs, Ipswitch, MA) and gel purification using the Qiaquick
gel extraction kit (Qiagen), the heavy chain fragment was subcloned into the SacI-ApaI site on
the PIGG vector. The light chain was amplified from the same template, using a 5’ primer that
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abolishes the SacI site and introduces a HindIII site, and a 3’ primer that binds to the 3’ end of
the J gene. The light chain constant region was amplified from a separate Fab-expressing vector,
then the light chain variable and constant regions were joined by overlap PCR. The overlap PCR
reaction was PCR purified, digested with HindIII and XbaI (New England BioLabs), and gel
purified (Qiagen) before being subcloned into the HindIII-XbaI site of the PIGG vector. A
complete set of primers is available in (368).
Px43 IgG1 and IgG4 were expressed and purified as previously described(368). Briefly,
endotoxin-free plasmid maxipreps (Qiagen) were transfected into five 10cm culture dishes of
HEK293T cells at approximately 70% cell density and DMEM plus 10% ultralow IgG fetal bovine
serum (Gibco/Life Technologies, division of ThermoFisher Scientific, Waltham, MA) using jetPEI
reagent (Polyplus-Transfection SA, Illkirch, France) according to manufacturers instructions.
Antibody was harvested on Day 3 and Day 6 from culture supernatant, by centrifuging nonadherent cells then neutralization of media by 1/100 volume 1M Tris pH 7.5. Antibody was
purified using Protein A agarose (ThermoFisher Scientific). After 2 hours of rotation at room
temperature, agarose was transferred to disposable chromatography columns, washed with 20
column volumes of PBS, eluted with 6 column volumes of 100 mM glycine pH 3, then neutralized
with 1/10 volume Tris pH 7.5. Concentration was determined by non-reducing SDS-PAGE
followed by Coomassie Blue staining, using an IgG standard.

2.3.3 Epitope Mapping
All epitope mapping vectors were generously provided by Masayuki Amagai. For epitope
mapping, extracellular full length and domain-swapped Dsg1/Dsg3 or Dsg2/Dsg3 molecules
were produced in the baculovirus-Sf9 system as previously described (226,384). For each
experiment, culture supernatants containing domain-swapped constructs were incubated with
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antibody followed by precipitation using protein A or protein G agarose. After boiling in Laemmli
sample buffer, beads are run on SDS-PAGE gel, then transferred to polyvinylidene difluoride
(PVDF) membrane. Immunoblotting was conducted using alkaline phosphatase-conjugated goat
antihuman IgG (Zymed Laborators, San Francisco, CA) for the Dsg1/Dsg3 swapped molecules
(because their C-terminus consists of the IgG1 constant region) or anti-E HRP (ab19400, Abcam,
Cambridge, MA) for the Dsg2/Dsg3 swapped molecules (because they express a C-terminal Etag)

2.3.4 Antibody ELISA
Dsg1 or Dsg3 ELISA (MBL International, Woburn, MA or Euroimmun, Luebeck, Germany)
was used to measure relative binding affinities of IgG subclasses. Serial dilutions of IgG1 and
IgG4 antibodies were incubated with Dsg1 or Dsg3 coated plates for 1 hour at room
temperature using kit sample buffer or TBS buffer containing 1mM CaCl2 and 5% dry milk. After
washing, bound antibody was detected using HRP-conjugated mouse monoclonal anti-human
IgG F(ab')2 (MBL International, Woburn, MA) or mouse monoclonal anti-human lambda (clone
JDC-12, Abcam). After 1 hour incubation at room temperature, plates were washed, developed
with 3,3’,5,5’ tetramethylbenzidine substrate, and optical density determined at 450 or 490 nm
using an automated plate reader.
Relative affinity was determined using regression analysis of double-reciprocal plots of
optical density versus antibody concentration. The relative constant was calculated as (1/y
intercept)*slope.
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2.3.5 Direct and Indirect Immunofluorescence
Direct immunofluorescence (DIF) was performed on frozen human skin sections after
mAb injection (see methods subsection on the human skin blistering assay – the same sample
was split after injection for DIF and H&E). Bound antibody in human skin was detected with
Alexa Fluor 594 anti-human IgG (Invitrogen, Grand Island, NY) in TBS buffer containing 1mM
CaCl2 and 1% BSA and visualized using an Olympus BX61 microscope.
Indirect immunofluorescence (IIF) was performed by incubating serial dilutions of mAb
on frozen normal human skin sections (obtained through the Penn Skin Disease Research
Center) in TBS buffer containing 1mM CaCl2 and 1% BSA. Bound antibody was subsequently
detected with FITC-conjugated anti-human lambda light chain (clone JDC-12, Abcam) and
visualized using an Olympus BX61 microscope. The titer is reported as the last dilution at which
epidermal cell surface staining is clearly positive.

2.3.6 Immunoreactivity Using Live Cell Staining ELISA
Human oropharynx epithelial tumor cell line, UM-SCC-47 (SCC-47), was obtained from
Dr. Thomas Carey, University of Michigan. Cell line was grown in 10% FBS-DMEM medium
containing 10% heat inactivated FBS, 2mM L-glutamine, 0.1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 10 µg/ml gentamicin. A live cell based ELISA was employed using SCC47 cells seeded in a 96-well flat bottom plate for two days. Serial dilutions of PV IgG1 and IgG4
mAbs and isotype control antibodies were added to the cells for one hour. After washing, bound
antibody was detected using biotin-conjugated goat anti-kappa chain antibody (1:5000)
(Southern Biotech, Birmingham, AL) for one hour. The plate was washed and HRP-conjugated
streptavidin (1:10,000) (SouthernBiotech) was added and incubated for 45 minutes. After a final
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wash, o-phenylenediamine (OPD) substrate (Sigma, St. Louis, MO) was added, and the plate was
incubated for 20 min and read at 490nm.

2.3.7 Human Skin Blistering Assay
All experiments using primary human skin samples were obtained using procedures
approved by the Institutional Review Board. Fresh normal human skin specimens (otherwise
discarded from excisional skin surgery) were obtained from the Penn Skin Disease Research
Center. Skin was trimmed of fat and cut into 5 mm sections. 25-50 µg of purified isotype mAb,
with or without 100 ng of Staphylococcus aureus exfoliative toxin A (ETA, Toxin Technology, Inc.,
Sarasota, FL) to inactivate Dsg1, was injected into skin sections, followed by incubation of skin
pieces on transwell inserts (Corning, Lowell, MA), with defined keratinocyte serum free media
(Invitrogen, Grand Island, NY) containing 1.2 mM CaCl2 in the outer compartment. Skin was
harvested at 16-24 hours for direct immunofluorescence (see methods subsection on
immunofluorescence) by embedding in OCT compound (TissueTek, Sakura, Netherlands) and for
histology by fixation in 10% phosphate buffered formalin.
Primary human epidermal keratinocytes (PHEK) obtained from the Penn Skin Disease
Research Center were treated with 50 µg/ml anti-Dsg3 mAbs for the indicated amount of time
during calcium-induced (0.07 mM shift to 1.2 mM calcium) desmosome assembly as described
(221). At 8 hours, cells were double-labeled with Alexa Fluor 594 anti-human IgG and mouse
anti-human Dsg3 (5G11) followed by Alexa Fluor 488 anti-mouse IgG, and nuclei were counterstained with DAPI.
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2.4 Results
2.4.1 IgG1 and IgG4 Variants of Pathogenic PV mAbs Recognize the Same
Antigenic Epitopes
Because the hinge region of IgG1 differs from IgG4, creating differences in the
orientation of the variable regions (253), Dsg3 affinity, epitope specificity, or blister-inducing
ability could be affected by the presence of the IgG1 versus IgG4 Fc. To explore this further,
IgG1 and IgG4 variants of pathogenic PV mAbs, bearing the identical variable region, were
generated.
To determine whether the IgG1 or IgG4 constant region affects epitope specificity, we
first tested F706 and F779 IgG1 and IgG4 mAbs against recombinant purified Dsg1 and Dsg3
antigens. ELISA showed that F706 and F779 IgG1 and IgG4 mAbs specifically bound to Dsg3 but
not Dsg1 (Figure 2-1A), indicating that the switch of constant region from IgG1 to IgG4 or from
IgG4 to IgG1 in these pathogenic antibodies did not affect Dsg isoform specificity. To further
define the epitope specificities, we performed conformational epitope mapping of IgG1 and
IgG4 mAbs using Dsg3 domain-swapped chimeric molecules. F706 and F779, both IgG1 and IgG4,
mapped to the first 161 amino acids of Dsg3 (Figure 2-1B). Similarly, Px43 IgG1 and IgG4
mapped to the same epitope within the first 101 amino acids of Dsg3. Thus, class-switched IgG1
and IgG4 variants do not change the variable region epitope specificity.

2.4.2 PV IgG1 versus IgG4 mAbs Demonstrate Similar Antigen Affinities
To determine whether IgG1 or IgG4 constant regions affect antigen affinity, we
evaluated IgG1 and IgG4 variants of pathogenic PV mAbs by ELISA and keratinocyte cell surface
staining. IgG1 and IgG4 variants of F706 and F779 show a similar level of binding to Dsg3 by
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ELISA (Figure 2-2A). The apparent affinity of F706 IgG1 and IgG4 mAbs for Dsg3 is 0.10 µM and
0.067 µM, respectively, and 0.015 µM or 0.021 µM for F779 IgG1 or IgG4, respectively.
Consistent with these data, binding isotherms of F706 and F779 IgG1 and IgG4 mAbs to Dsg3+
human oropharynx keratinocyte tumor cells by immunolabeling are similar (Figure 2-2B). Px43
IgG1 demonstrates 8-fold and 3-fold lower affinity for Dsg3 and Dsg1 than Px43 IgG4 by ELISA
(Figure 2-2A); however their human skin IIF titers are identical at 0.5 ng/µL (Figure 2-2C).

2.4.3 PV mAb IgG1 Versus IgG4 Demonstrate Comparable Blister Forming
Ability in Human Skin Explants
We next investigated the blister-inducing ability of IgG1 and IgG4 recombinant mAbs, to
determine whether IgG subclass could play a role in modulating the pathogenic effects of Dsg3reactive variable regions. In skin, Dsg1 can provide compensatory adhesion if Dsg3 is inactivated
(235,385). Consequently, human skin assays to determine blister-inducing ability of anti-Dsg3
mAbs require inactivation of Dsg1, for example by co-injection of Staphylococcal exfoliative
toxin A (ETA), which specifically cleaves Dsg1 (386). We injected 25-50 µg of anti-Dsg3 IgG1 or
IgG4 mAbs, plus or minus ETA as required, into human skin sections, followed by incubation for
16-24 hours prior to harvest for immunofluorescence and histology. F706, F779, and Px43 all
caused suprabasal blisters at comparable doses of IgG1 and IgG4 (Figure 2-3A). A similar extent
of blistering was observed at both 25 µg and 50 µg doses (Figure 2-3B). Direct
immunofluorescence of injected skin sections showed comparable binding of PV IgG to the cell
surface of keratinocytes (Figure 2-3C).
Previously, pathogenic but not non-pathogenic human PV mAbs were shown to cause
Dsg3 internalization in primary human keratinocytes (221). Consistent with these studies,
primary human keratinocytes treated with F706, F779, or Px43 IgG1 and IgG4 exhibited
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depletion of cell surface Dsg3 within 4 hours after antibody treatment, concomitant with an
increase in cytoplasmic vesicular staining of Dsg3 (Figure 2-4). Thus, IgG1 and IgG4 variants of
F706, F779, and Px43 comparably induce loss of cell surface Dsg3 in primary human epidermal
keratinocytes and suprabasal blisters in human skin.

2.5 Discussion
This study demonstrates that epitope specificity, antigen affinity, and blister-inducing
ability of PV mAbs are not directly affected by the presence of the IgG1 versus IgG4 constant
region. Although our conclusions are limited by the study of only three mAbs, these mAbs were
cloned from 3 different patients and represent three distinct types of pathogenic PV mAbs that
have been described in the literature, including anti-Dsg3 IgG1, anti-Dsg3 IgG4, and a crossreactive anti-Dsg3/Dsg1 IgG.
All PV mAbs tested in this study bind the Dsg3 extracellular cadherin (EC) 1-2 domains
that are crucial for cis- and trans-adhesive interactions of the Dsgs. This result agrees with a
previous large scale mapping study of PV sera in which 91% of PV sera mapped to the Dsg3 EC1
domain (226).
Although F706, F779, and Px43 all demonstrated comparable antigen affinity of IgG1
and IgG4 variants by ELISA and/or IIF staining, Px43 IgG1 and IgG4 were notable for
demonstrating differing results by ELISA and IIF. Px43 was previously shown to recognize only
mature conformational Dsg3 (387) and by surface plasmon resonance binds Dsg3 with complex
kinetics that best fit to a conformational change model (367). It is possible that Px43 binds a
quaternary epitope in Dsg3 and Dsg1 that is predominant in native human skin but may be
differentially displayed in ELISA, which may account for the difference in relative affinities
observed between IgG1 and IgG4 variants. Nevertheless, these results indicate that the binding
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affinity of Px43 variable regions to Dsg3 in human skin is not significantly altered by the
presence of the IgG1 versus IgG4 constant region.
No change of blister-inducing ability among PV IgG1 and IgG4 mAb variants was
observed, either in regard to Dsg3 internalization or the ability to cause suprabasal blisters in
human skin. These data are consistent with the finding that the constant region is not required
for blister formation in PV (377) or for Dsg3 internalization after monovalent PV mAb binding
(221). Our data now further indicate that the IgG1 versus IgG4 constant region does not
modulate the functional effects of pathogenic PV mAbs in regard to either Dsg3 internalization
or suprabasal blister induction.
With no difference in pathogenicity, the question arises as to why IgG4 is preferentially
associated with active disease. IgG4 is typically observed in conditions of chronic antigen
stimulation, such as in individuals undergoing allergic desensitization or beekeepers (253). Class
switch recombination is a complex process regulated by cytokines (388). IL-4 has a central role
in stimulating antibody class switch (389). CD40 and IL-4 can initiate class switch by inducing
enzymes and other transcripts required for site-specific DNA recombination. IgG1 is the most
abundant serum IgG subclass, in part due to its proximal location within the constant region
locus. Repeated antigenic exposure can encourage subsequent isotype switching. IL-4 and IL-13
promote isotype switching first to IgG4 and subsequently to IgE (390), whereas IL-10 and IL-21
potentiate IL-4-induced switching to IgG4 over IgE (391,392). Upregulation of the Th2 cytokines
IL-4, IL-5, IL-10, and IL-13 has been described in pemphigus patients (393,394). These cytokines
would promote an IgG4>IgG1 serum antibody profile, coinciding with the spectrum of observed
autoantibody isotypes in patients with active disease. A deeper understanding of how
pathogenic variable regions segregate among the IgG subclasses would require isotype-specific
antibody cloning, as seen in chapter 3.
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In summary, we have found that subclass-switching between IgG1 and IgG4 constant
regions has no significant effect on epitope specificity, antigen binding affinity, or blisterinducing ability in 3 human PV mAbs isolated from 3 different PV patients. Although limited by
the study of only three antibodies, this study provides the first direct evidence that the
immunochemical and pathogenic properties of PV pathogenic variable regions are not
significantly modulated by antibody subclass, supporting the conclusion that the antibody
variable region is most important for determining pathogenicity in PV. The possible ontogeny of
the variable region in PV, and specifically the lineage relationships between anti-Dsg variable
regions in PV, will be further investigated in chapter 3 of this thesis.
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2.6 Figures and Tables

Figure 2-1. IgG1 and IgG4 PV mAbs target epitopes within the same Dsg3 extracellular
domains. (A) F706 and F779 mAbs bind desmoglein 3 (Dsg3) but not Dsg1. Subclass-switched
anti-human Dsg3 F706 and F779 IgG1 and IgG4 were tested by ELISA for binding to Dsg3 and
Dsg1. Negative and positive controls were provided by the manufacturer. F71 IgG1 and b12 IgG4
antibodies served as isotype controls. (B) Deduced epitopes of IgG1 and IgG4 variants of PV
mAbs show that mAb pairs recognize epitopes within the same Dsg3 extracellular domains.
Assay was considered positive if immunoblot showed a band at the correct size.
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Figure 2-2. Immunoreactivity of anti-Dsg3 PV mAbs by ELISA and IIF. (A) Serial dilutions of
recombinant human IgG1 (♦) or IgG4 (□) variants of mAbs (F706 against Dsg3 in upper left ,
F779 against Dsg3 in upper right, Px43 against Dsg3 in lower left and Px43 against Dsg1 in lower
right) were incubated with Dsg3- coated ELISA plates. Bound antibody was detected using HRP
conjugated mouse anti-human (H+L) Ab. Results are the mean of duplicate wells and are
representative of 2-3 independent experiments. The relative affinity of each Ab was calculated
by Lineweaver-Burk plot. (B) IgG1 and IgG4 variants of F706 and F779 mAbs show comparable
immunoreactivity to the Dsg3+ human oropharynx tumor cell line SCC-47. F71 IgG1 and b12
IgG4 served as isotype controls. Other negative controls included HRP substrate OPD added
alone or with secondary reagents only (secondary (2nd) biotinylated anti-human Fc Ab (Biotin
Ab) or 2nd Ab with HRP-conjugated streptavidin Ab (Bio + SA Abs) in absence of tested PV mAbs.
OPD: o-phenylenediamine dihydrochloride. (C) Px43 IgG1 and IgG4 demonstrate different
relative affinities by ELISA but comparable affinity by indirect immunofluorescence (IIF) binding
of human skin (red box). D: dermal part of skin. Results are representative of 1-2 experiments.
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Figure 2-3. IgG1 and IgG4 variants of anti-Dsg3 PV mAbs are pathogenic and cause suprabasal
blisters in human skin. (A) 25 µg anti-Dsg3 PV IgG1 or IgG4 was injected ex vivo into human skin
sections and incubated for 18 hours prior to harvest for histologic analysis. IgG1 and IgG4 of
three anti-Dsg3 PV mAbs, F706, F779 and Px43 induced suprabasal blisters in human skin.
PBS/ETA served as negative control. Scale bar, 100 microns. (B) The extent of histologic
blistering caused by IgG1 and IgG4 mAb variants is comparable. (C) Direct immunofluorescence
(DIF) staining of human skin with PV isotype mAbs illustrates cell surface binding in skin
epidermis following injection of mAbs. D: dermal part of skin. Scale bar, 20 microns.
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Figure 2-4. Pathogenic F706 and F779 IgG1 and IgG4 cause loss of cell surface Dsg3. Primary
human keratinocytes were incubated for 8 hours with 50 µg/mL F706/F779 IgG1 or IgG4. Cells
were prepared for IF staining using anti-human IgG or anti-Dsg3 (5G11) primary antibodies. Px44
negative and Px43 positive control antibodies were previously characterized (386). Scale bar, 20
microns. Results are representative of two independent experiments.
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CHAPTER 3:

Lineage Analysis of Immune Repertoires in Pemphigus Vulgaris Reveals
Distinct Pathways for Development of Autoreactive IgG4 versus IgG1 and
IgA B Cells

3.1 Abstract
Analyzing lineage relationships among autoreactive B lymphocytes is key to
understanding the origins of autoimmunity. In pemphigus vulgaris (PV), characterized by
blistering of the skin and mucosa, autoreactive anti-desmoglein (Dsg) antibodies
predominantly belong to the IgG4 antibody subclass, and less prominently IgG1 and IgA.
This compelled

us to investigate whether anti-Dsg IgG4 B cells share lineages with anti-

Dsg clones from the IgG1, IgA1, and IgA2 subclasses, suggestive of either evolution from
common precursors or direct parent-child relationships. By sequencing B cell repertoires
from the blood of four PV patients, we were able to sample over 70% of the circulating B
cell lineages of each of subclass in each patient. We combined this approach with
subclass-specific antibody phage display to identify and mark Dsg-reactive lineages
within the larger repertoire. After identifying several Dsg-reactive lineages bridging
subclasses, we found that the majority of anti-Dsg IgG4 B cells lack identifiable
circulating relatives in other antibody subclasses. Specifically, direct IgG1-IgG4 switching
comprises a minority pathway for the development of anti-Dsg IgG4 B cells, even when
circulating IgG1 and IgG4 B cells appear to share a lineage. Within circulating anti-Dsg B
cell lineages, parent-child relationships were observed between IgA1 and IgA2, between
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IgG1 and IgA1, and between IgG4 and IgA2, indicating that IgA B cells in PV often derive
either directly from or independent of IgG B cells and often switch between IgA1 and
IgA2 subclasses. These findings suggest that class-switching between IgG and IgA may
serve as a disease-modifying pathway in PV, and that the reciprocal relationship
between IgG1 to IgG4 observed in chronic antigen stimulation may be in part due to the
production of new antigen-specific lineages from non-IgG1 subclasses, rather than
sequential class-switching of already extant IgG1 clones.

3.2 Introduction
The staggering sequence diversity of antibody variable regions comes at a price –
the generation of autoreactive clones alongside those required to protect from
pathogens (140,395). While the variable region determines antigen reactivity, the
antibody constant region confers diverse effector functions (e.g. agglutination,
complement fixation, and activation of different leukocyte populations through Fc
receptors) that can also contribute to the pathogenesis of autoimmunity by causing endorgan damage (396,397). During clonal expansion and affinity maturation, B cells can
change their constant region to one of nine subclasses by recombining the IgH constant
region locus – a tightly-regulated process known as class switching (388). While most
current knowledge on human B cell class switch pathways derives from in vitro
experiments (398,399), the advent of high-throughput sequencing has recently allowed
the collection of large-scale in vivo data on class-switch relationships in normal and
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allergic individuals (133)(137). However, very little is known about class switch pathways
that contribute to human autoimmunity.
An ideal disease for investigating the potential role of class switch in
autoimmunity, pemphigus vulgaris (PV) is a potentially fatal condition in which
autoantibodies against the keratinocyte adhesion protein desmoglein 3 (Dsg3) induces
mucosal blistering, with subsequent development of antibodies to Dsg1 causing wider
skin involvement in its mucocutaneous subtype. Similar to other autoimmune diseases
(242), PV patients with active disease demonstrate predominantly anti-Dsg IgG4 and
less so anti-Dsg IgG1 (243); PV autoantibodies do not appear to associate with IgG2 and
IgG3 subclasses (243,246). This anti-Dsg IgG4 predominance is so pronounced that PV
patients demonstrate enrichment of total serum IgG4 (244). Intriguingly, whereas PV
patients with active disease demonstrate anti-Dsg3 IgG1 and IgG4, unaffected relatives
of PV patients (rarely), HLA-matched controls (rarely), and PV patients in remission can
demonstrate anti-Dsg3 IgG1 (245,378). Th2-type cytokines such as interleukin-4 can
stimulate B cell class switch to both IgG1 and IgG4 (400), although whether this switch
occurs independently or sequentially is unknown. Additionally, the majority of PV
patients demonstrate serum anti-Dsg IgA during active disease (243,258,259). Given
that disease often begins in the mucosa and mucosal IgA plasmablasts can be selfreactive or polyreactive even in non-autoimmune subjects (265), IgA B cells could serve
as an origin for autoreactive IgG4 clones.
The existence of multiple subclasses of autoantibodies targeting the same
antigen suggests that class-switching is likely an important mechanism of pathogenesis
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and diversification of the autoreactive B cell response in PV, and led us to investigate
the origin of autoreactive B cells, particularly IgG4 B cells. To trace the developmental
pathway of autoreactive B cells in PV across four key subclasses (IgA1, IgA2, IgG1, and
IgG4), we paired deep sequencing of subclass-specific B cell repertoires with antibody
phage display against Dsg to identify antigen-specific heavy chains, allowing us to
simultaneously identity anti-Dsg clones and . This combined approach allowed us to
both characterize the global lineage relationships between these four subclasses and to
define the class-switch pathways that lead to the formation of autoreactive B cells in PV.

3.3 Materials and Methods
3.3.1 Peripheral Blood Collection and Processing
Phage display libraries were produced as previously described (401), with minor
modifications to generate biological replicates and facilitate the production of IgG1,
IgG4, IgA1, and IgA2 specific amplicons for Next Generation Sequencing (NGS) and
antibody phage display. In brief, 60 mLs of lithium-heparin anticoagulated peripheral
blood was collected by venipuncture from four patients (PV8, PV16, PV17, PV18)
following informed consent using an Institutional Review Board-approved protocol.
Patient characteristics can be found in Table 3-1. The diagnosis of PV was established by
typical clinical presentation, histology and immunofluorescence. For PV17 and PV18,
two separate 30 mL blood samples were collected on the same day and processed
independently to evaluate reproducibility among biological replicates.
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Peripheral blood mononuclear cells (PBMCs, ~108 per 60 mL blood) were isolated
by Ficoll-Paque Plus (GE healthcare) gradient centrifugation according to the
manufacturer’s recommendations and snap-frozen in methanol prior to storage (-80oC)
and further processing.

3.3.2 Library Preparation and Sequencing
Total RNA was isolated from PBMCs after rotor-stator-mediated cell
disruption/homogenization (Omni international) with the RNeasy Midi Kit (Qiagen)
according to the manufacturer’s recommendation. The typical yield from 108 PBMCs
was 60-120ug of total RNA. Oligo-dT primed mRNA was reversely transcribed into cDNA
in 15ug batches and subsequently destroyed by RNase digest with the Superscript First
Strand synthesis system for RT-PCR (Thermo Fisher) following the manufacturer’s
protocol. In order to create NGS and phage display compatible amplicons, cDNA
(equivalent of 7-8ug total RNA for each subclass) was subjected to 30 cycles of PCR with
primers targeting the 5’ end of the VH gene and the hinge region of the respective
isotype subclass (subsequently called 1st round PCR reaction). The 1st round PCR
reaction was conducted with Platinum Taq high fidelity polymerase (Thermo Fisher) as
opposed to proof reading enzymes with lower error rate to maximize the yield and
diversity of the libraries and all subsequent steps. PCR products were identified by gel
electrophoresis, purified (Wizard SV PCR Clean-Up system, Promega) and reamplified in
a semi-nested manner with primers for the 5’ end of the VH gene and primers targeting
the 5’ end of the first constant region (CH1), leaving the first 9 nucleotides of this region
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unprimed to allow for identification of the original template encoded isotype (i.e. IgA vs.
IgG; this is subsequently called the 2nd round PCR reaction). The primer position at the 5’
end of the CH1 harbors 2 distinct advantages that we reasoned were essential: (1) it
allows the isotype to be directly confirmed from the template (as opposed to using J
gene primers), while (2) it maximizes the length of the overlap during assembly of the
paired end NGS reads, thereby creating higher confidence base calls in a 150 base pair
window including CDR1, CDR2 and a significant proportion of the CDR3.
We generated phage display and NGS libraries from the same first round
amplicon by modifying the flanking regions of the 2nd round PCR primers: In case of
further processing for antibody phage display, the primers of the 2nd round PCR reaction
were flanked by sequences encoding the GS-linker (5’ primer; to be overlapped with the
light chain amplicons for generation of scFvs) and a library-specific signature (3’ primer,
to exclude phage-mediated contamination during library screening).
NGS libraries were generated with 2nd round PCR primers that were flanked by a
transposase sequence (5’ and 3’ primers) and in addition encoded a library-specific
signature (3’ primer only), thereby implementing a triple protection against falsely
assigned cross-isotype relationships: the template-encoded isotype-specific start of the
CH1 region, the library-specific signature, and the amplicon-specific Illumina barcodes.
In order to minimize sampling error, 2nd round PCRs were performed with 3 and 6
technical replicates per primer combination for phage display libraries and NGS,
respectively. Subsequent processing of the amplicons for phage display and NGS is
described in the following 2 sections.
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3.3.3 Antibody Phage Display
To identify Dsg-reactive heavy chain sequences in the deep sequencing data,
antibody phage display libraries were constructed using the aforementioned isotypespecific VH amplicons generated during 30 cycles of 2nd round PCRs. For PV17 and PV18,
1st round PCR products were produced for each biological replicate and subjected to 2nd
round PCR amplification after equimolar pooling. These VH amplicons were fused by
overlap extension PCR with VL amplicons to create scFv sequences with the
configuration VL-GS-linker-VH. The scFvs sequences were flanked by SfiI sites
(introduced during overlap extension PCR), which allows for directional cloning into
pComb3X as previously described (208). Electroporation (Micropulser Electroporation
apparatus, Bio-Rad, 12.5 kVcm-1, exponential decay with time constants between 3.44.0ms) of libraries into XL-1 blue cells (Agilent) achieved a total number of 108-109
transformants per library. Libraries were generated and screened separately. All
libraries were panned separately against Dsg3 and Dsg1 at room temperature for three
to five rounds of panning, with the exception of PV16 IgG4 and PV16 IgG1, which were
panned against Dsg3 and against Dsg3 and Dsg1 in alternation (in the order 3,1,3,1). Up
to 200 colonies were analyzed for each patient from all rounds of panning that showed
binding to Dsg1 or Dsg3 by pooled phage ELISA.
Unique clones were produced as soluble scFv in E. coli. In brief, 2ul of plasmid
was added to 5-10 ul of Top10F’ cells, then transformed and plated on LB/ampicillin
plates according to the manufacturer’s instructions. Single colonies were diluted into
20mL SB containing 20mM MgCl2 and 0.05 mg/mL carbenicillin, grown overnight at 30C,
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then diluted 1:100 in 400mL of SB with the same concentration of MgCl2 and
carbenicillin. Cultures were grown to OD600 of 0.5-1.0, then induced with 1mM IPTG
and grown at 30C for an additional four hours (which was further optimized for some
clones to improve production). Cultures were spun down and pellets were re-suspended
in 30-35 mL of FastBreak lysis reagent (Promega), then processed and subject to cobalt
affinity chromatography (Talon, Clontech) according to the manufacturer’s instructions.
Purified scFv concentration was determined by SDS-PAGE followed by Coomassie blue
staining, using BSA standards for quantitation.
Cloned scFv were validated using indirect immunofluorescence at 50 mg/mL on
frozen normal human skin sections (obtained through the Penn Skin Disease Research
Center) in TBS buffer containing 1mM CaCl2 and 1% BSA. Bound antibody was detected
with rat anti-HA antibody (3F10, Roche), then by 1:200 Alexa Flour 594 donkey anti-rat
IgG (Thermo Fischer Scientific). IF was visualized using an Olympus BX61 microscope,
images acquired using SlideBook 4.2 software (Olympus) and a Hamamatsu Orca ER
camera.
Cloned scFv were also tested by ELISA against Dsg3, Dsg1, and an irrelevant
antigen (either tetanus toxoid or BP180) as a negative control (Euroimmun), performed
according to manufacturer’s instructions.

3.3.4 Next Generation Sequencing
Isotype-specific 1st round PCR VH amplicons were amplified with 2nd round PCR
primers as mentioned above. In order to minimize PCR induced mutations, the NGS
76

libraries were produced with Q5 polymerase (NEB) using a maximum of 3ng per reaction
and only 12 PCR cycles. After visualization and purification (Wizard SV PCR Clean-Up
system, Promega), the 2nd round product concentration was quantified (NanoDrop,
Thermo Fisher) and PCR products were pooled with equal amounts of DNA input
representing each primer pair. Subsequently, pooled PCR products were subjected to 12
cycles of PCR amplification to attach the Illumina Nextera barcodes and adapters,
followed by gel purification (Wizard SV gel purification system, Promega) and additional
purification with AmPure beads (Beckman Coulter) according to the manufacturer’s
recommendations. NGS library concentrations were determined (Qubit dsDNA HS,
Thermo Fisher) and pooled accordingly. The concentration of sequencing-competent
amplicons was additionally analyzed by qPCR (KAPA Biosystems), and the purity was
confirmed (Bioanalyzer, Agilent) before subjecting the amplicons to paired end 2x300
base pair sequencing (Illumna MiSeq). In order to estimate the frequency of artificial
mutations introduced during library production and sequencing, we generated an
additional amplicon with comparable length derived from a Sanger sequencing-verified
plasmid encoding the CD8-CD137 transition of a chimeric antigen receptor (CAR). The
plasmid was subjected to the same number of PCR cycles and procedures as the
abovementioned amplicons and added to the library mixture comprising 1% of the total
amount of DNA (as determined by Qubit).
Technical replicates were generated by production of 2 NGS libraries from the
same cDNA with identical primers (except for barcodes and signatures) and sequencing
those 2 libraries separately. Biological replicates were generated by processing 2 blood
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samples (so that B cell clones shared between the replicates have to be derived from
each aliquot and therefore represent physically separate B cells) separately for NGS
library production.

3.3.5 Raw Data Processing and Lineage Clustering
Libraries were sequenced as mentioned above using Illumina Miseq 300bp
paired end sequencing (Institute for Genome Science, University of Maryland; NextGeneration Sequencing Core, University of Pennsylvania). Forward and reverse reads
were merged using PEAR (402), and identical reads were merged into non-redundant
(NR) sequences. All non-redundant sequences with isosignature exactly matching the
predicted isosignature for a given library were kept, and uploaded to IMGT-Hi-VQUEST
for VDJ assignment. The IMGT results were filtered to only productive hits.
Clonality was defined by first binning all sequences from all four patients by V, J
and CDR3 length, then for each bin calculating the nearest neighbor nucleotide
hamming distance from a given CDR3 to all CDR3 in the same V-J-length bin belonging to
another patient. This allowed us to define an upper limit on allowed clonal divergence. A
per-patient nucleotide hamming distance cutoff was selected such that the resulting
clusters would have 99% confidence of unrelated sequences being excluded. Sequences
within each patient-subclass pair were then clustered using a customized perl script and
a centroid (UPGMC) linkage function implemented in the Algorithm::Cluster module.
Within each patient-subclass pair, clusters were subsequently superclustered by their
consensus CDR3 sequence, without regard to VDJ gene assignment, and only the cluster
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with the largest number of reads (toprank) was considered for large scale subclass
connectivity analysis. Heavy chains found by phage display were matched back to NGS
clusters by searching for consensus CDR3 falling within the original clonality CDR3
nucleotide identity cutoff for each patient.

3.3.6 Estimation of Clonal Richness/Diversity and Total Population Size
To estimate the total population size and the fraction of the total population that
was captured by sequencing, all biological and technical replicates for a given subclasspatient pair were pooled and subject to rarefaction analysis and asymptotic diversity
estimation using the iNEXT package in R (304) and the online implementation of iNEXT
(http://chao.shinyapps.io/iNEXTOnline/). Each supercluster was treated as a “species”,
and abundance-based rarefaction was conducted on the number of reads. Furthermore,
in order to determine the amount of total diversity in the sample capture, the
asymptotic Shannon Diversity, Simpson Index, and Species Richness were compared to
the actual values for those metrics in a given sample. To correct for the artificial inflation
of low-abundance taxa due to sequencing and amplification error, the number of
singletons in each sample was deflated using the formula presented in (309):
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To determine the reproducibility of lineages among technical and biological
replicates, capture-recapture analysis was performed using the Chapman estimator
(298):

A lineage was considered existing in one replicate if it appears with five reads in that
replicate, and existing in both replicates if it appears with at least five reads in each
replicate in question.

3.3.7 Quantitation of Subclass Connectivity
Average pairing rates between subclasses were computed as the harmonic mean
of the frequency of shared lineages appearing between the subclasses, in order to
normalize for differing subclass sizes. For example, if n lineages are shared between
subclasses of read size A and B, the pairing rate is
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For comparing pairing rates between the anti-Dsg and global repertoire, the
calculated pairing rate was bootstrapped down to the size of the anti-Dsg repertoire for
any given subclass pair.

3.3.8 Lineage Analysis
Lineages of interest were selected as those phage-display-derived heavy chain
sequences mapping to top-rank clusters in other subclasses with at least 5 reads, with
an additional constraint that the top-rank cluster in the “home” subclass of the Dsgreactive clone have an identical V-gene (without consideration of the allele). Sequences
within each lineage of interest were subject to primer trimming and full-length
clustering at 97% radius using the cluster_otus command in USEARCH (315). Trees were
drawn after removing all nodes with fewer than 5 reads. For visualization, some trees
were drawn with all nodes with fewer than 10 reads removed, though this did not affect
their topology. Parameters were tested on a monoclonal CD137 template subject to the
same amplification procedure as the libraries (Figure 3-23). In total, 19 trees were
produced (Table 3-2). Maximum parsimony trees were generated using the Change-O
package (116), which calls dnapars.exe from PHYLIP (403). Intermediates from
maximum parsimony trees were synthesized as gblock gene fragments (Integrated DNA
Technologies) with nucleotide additions allowing either overlap PCR with the
corresponding light chain or direct cloning into the pComb3X vector.
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3.3.9 Epitope Mapping
Epitope mapping was performed as previously described for patient sera (22)
and scFv (24), using chimeric Dsg3/2 or Dsg1/2 molecules expressed in either baculoviral
or HEK293-derived supernatants. Dsg3-reactive clones were tested by
immunoprecipitation against Dsg3/2 constructs followed by western blotting using an
anti-E-tag HRP antibody, and Dsg1-reactive clones were tested against Dsg1/2
constructs in an analogous manner

3.4 Results
3.4.1 High-Throughput Sequencing of Subclass-Specific B Cell Repertoires
in PV Indicates a Predominance Of Anti-Dsg IgG4 Lineages, Followed by
IgA1, IgG1, and IgA2
A better understanding of the isotype relationships of autoreactive B cells
requires deep sequencing of B cell repertoires to obtain large-scale B cell lineage
information, as well as a method for identification of antigen-specific clones. We
performed high-throughput sequencing of IgG4, IgG1, IgA1, and IgA2 B cell repertoires
in a panel of four PV patients with active disease (patient characteristics can be found in
Table 3-1). RNA was isolated from PBMC derived from 50-60 mL of peripheral blood,
representing approximately 2 x 106 class-switched B cells ([50 mL of blood] x [4 x 105 B
cells/mL of blood] x [10% B cells are class-switched]), per patient. Sequencing libraries
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were prepared from an amplicon generated using a 3’ primer specific for the unique
hinge region of each subclass. Subsequent amplification for library production was
conducted using a 3’ primer containing a constant-region-specific binding sequence, a
custom library barcode for every patient-subclass pair, and an Illumina index sequence.
The constant region sequence and the library barcode were collectively called the
isosignature (Figure 3-1). Ensuring the index sequence and isosignature were
concordant allowed high-confidence discrimination between subclasses and stringent
filtering of potentially mis-assigned sequences that would be falsely interpreted as
cross-subclass relationships. This amplification scheme allowed us to generate ~225,000
to ~6 million paired-end raw reads per patient-subclass pair on the Illumina MiSeq
2x300 bp platform (Table 3-3). Furthermore, each sequencing run was accompanied by
a monoclonal template subject to the same amplification steps, to give a bound on
amplification and sequencing-induced error.
Antibody phage display libraries were prepared from the same hinge-primed
amplicon and panned against Dsg3 and/or Dsg1 to select subclass-specific Dsg-reactive
clones. Across 16 libraries representing four patients and four subclasses, each
representing 100 million to 1 billion total transformants, up to 200 clones were
characterized for anti-Dsg ELISA reactivity and cell-surface staining by indirect
immunofluorescence to independently verify the PV phenotype, resulting in 96 total
unique anti-Dsg B cell clones representing 80 lineages (Table 3-4). Characterized clones
showed a wide variety of V-gene usage and a lack of stereotyped CDR3 sequences,
demonstrating a highly polyclonal anti-Dsg response across subclasses. The plurality of
83

unique Dsg-reactive clones belong to the IgG4 subclass (34), followed by 21 IgA1 clones,
18 IgG1 clones, and 13 IgA2 clones. We found a comparable number of IgA and IgG4
clones among the four patients (34 of each), suggesting a diversified anti-Dsg response
in both the IgG and IgA isotypes.

3.4.2 Anti-Dsg Clonal Lineages Bridge Multiple Subclasses
After sampling anti-Dsg clones from each of the sixteen subclass-patient
libraries, we first sought to determine the lineage relationships of these Dsg-reactive
clones across the four sequenced subclasses. To that end, we determined the clonal
structure of the global antibody repertoire by partitioning sequences into lineages. First,
across all patients, sequences sharing V, J, and CDR3 length were binned together. Then,
by comparing the CDR3 sequences from each of the four patients against the other
three, we derived a per-patient CDR3 nucleotide identity cutoff that gives 99%
confidence that two clustered sequences do not belong to different lineages (Figure 32). CDR3 nucleotide similarity cutoffs ranged from 80.6% in PV8 to 86.1% in PV18.
Finally, to mitigate the effects of VJ misassignment and sequencing error creating
spurious lineages, we further grouped all clusters together that meet the same CDR3
cutoff, without requiring matching V or J genes; this allowed us to sort clusters by read
count into ranked lists called superclusters, and to eliminate non-top-ranked clusters
within a supercluster from consideration during lineage analysis to improve stringency.

84

We subsequently mapped the phage-display derived heavy chain sequences to
deep-sequencing derived clonal lineages, finding 80 Dsg-reactive lineages that span
between one and four subclasses (Figure 3-3a). We further analyzed these 80 Dsgreactive lineages in terms of pairwise overlaps between subclasses (Figure 3-3b and 33c), which demonstrated that a majority of IgA1- and IgA2-containing Dsg-reactive
lineages contain relatives in other subclasses; in particular, the majority of IgA1 have
relatives in IgA2 and vice versa. By contrast, only a minority of IgG4-containing Dsgreactive lineages can be found in other subclasses. It is noteworthy that when IgG4containing lineages bridge subclasses, that they show a slight preference for IgG1 (21%)
over IgA1 (15%) and IgA2 (13%). To determine whether IgG4 is unique among subclasses
in its lack of relationships, we compared the proportion of single-subclass and multisubclass Dsg-reactive lineages between all four subclasses (Figure 3-3d). Only 28% of
IgG4-containing Dsg-reactive lineages are multi-subclass, which, by Fisher’s exact test, is
significantly fewer than the other three subclasses combined (P = 6.31 x 10-6).

3.4.3 Large-Scale Clonal Analysis Indicates anti-Dsg IgG4 B cells Show
Increased Connections to Other Subclasses Relative to IgG4 B cells in the
Global Repertoire
We have demonstrated that the anti-Dsg IgG4 repertoire is disconnected from
other subclasses compared to anti-Dsg lineages in other subclasses, and that the antiDsg IgA repertoire is highly connected. To determine whether this is a unique feature of
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the anti-Dsg repertoire relative to the global B cell repertoire, we next sought to
compare the connectivity of the anti-Dsg B cell repertoire to the global repertoire. To
understand the large-scale structure of the repertoire, we calculated the average pairing
rate of each subclass pair by taking the harmonic mean of the proportion of overlapping
lineages between a given subclass pair (see Methods). First, we compared the betweensubclass pairing rate of the Dsg-reactive and global repertoire for all four patients and all
four subclasses. This demonstrated that the Dsg-reactive repertoire is significantly more
interconnected than the global one (p < 0.0001, Figure 3-4a). Separating out the Dsgreactive repertoire by subclass shows that IgA1 and IgA2 show the highest
interconnectedness, both in the global and Dsg-reactive repertoires (Figure 3-4b).
We next determined the subclass pairings which were enriched in the Dsgreactive repertoire in order to determine lineage relationships important in PV. For each
of the six possible subclass pairs, we normalized the pairing rate of the Dsg-reactive
repertoire to the global repertoire (Figure 3-4c). To account for the possibility that this
increase in IgG4 connectivity is simply a positive correlation with lineage size, we
compared the number of reads mapping to the IgG4 subclass in single-subclass anti-Dsg
lineages vs multi-subclass anti-Dsg lineages containing IgG4 in each patient. No
significant difference in IgG4 read number between multi-subclass and single-subclass
autoreactive lineages was found, indicating that lineage size and/or sampling depth
appears to have a minimal effect on connectivity (Figure 3-4d). Though it remains
isolated in an absolute sense, the Dsg-reactive IgG4 repertoire shows an increased
connectivity to other subclasses compared to anti-Dsg lineages in the global repertoire.
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3.4.4 Anti-Dsg IgG4 B Cells Predominantly Demonstrate No Subclass
Connectivity but can Rarely Switch Directly From anti-Dsg IgG1 B Cells
Our global repertoire data demonstrates that anti-Dsg IgG4 is disconnected from
the larger anti-Dsg repertoire relative to other subclasses. Of the 39 total IgG4containing Dsg-reactive lineages, 28 contained sequences from only IgG4, while 11
contained sequences from multiple subclasses (Figure 3-3d). To better understand the
clonal development of the Dsg-reactive IgG4 repertoire on a fine level, we further
analyzed seven lineages containing both IgG4 and IgG1 by generating maximum
parsimony phylogenetic trees for each lineage (Figure 3-5, 3-6, 3-7, 3-8). 1/7 of these
lineages showed evidence of a direct IgG1 to IgG4 switch, with the IgG1 clone differing
from the IgG4 clone by a single substitution (Figure 3-5a). The remainder do not show
an identifiable direct switch between IgG1 and IgG4, either due to very early divergence
from germline and subsequent independent evolution of each subclass (Figure 3-5b, 37), late divergence after some mutation of a precursor (Figure 3-5c), or show coevolution and intermingling between IgG1 and IgG4 without evidence of direct class
switch (Figure 3-5d).
To understand the onset and development of Dsg reactivity within each lineage,
we produced several selected sequenced and inferred nodes from seven of the IgG4containing multi-subclass lineages and several sequences with a germline-reverted
heavy chain from lineages containing only IgG4 Dsg3. ELISA indicated that in all except
one multi-subclass lineages tested, relatives of Dsg-reactive clones in other subclasses
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showed similar ELISA reactivity (Figure 3-21a); only the PV17.G1.D1.P4.8 lineage (Figure
3-5d) showed no reactivity in other subclasses. Furthermore, in multi-subclass lineages
with confirmed reactive sequences across multiple subclasses, 4/6 most recent common
ancestors (MRCA) and 8/11 germline heavy chain sequences (Figure 3-21b) show strong
anti-Dsg reactivity mirroring the reactivity of phage-display derived clones and
sequenced nodes.

3.4.5 Anti-Dsg IgG4 B Cells Evolve Independently of IgA1 but can Directly
Give Rise to anti-Dsg IgA2 B Cells
As PV blistering often begins in the mucosa, we next sought to identify potential
direct-switch relationships between IgA clones and IgG4 that could imply a mucosal
origin for autoimmune B cells in PV. Anti-Dsg3 IgG4 clones share three lineages with
IgA2 and two with IgA1. IgA1 and IgG4 show no evidence of direct switching, lying on
different branches of the two analyzed lineages in which they coexist (Figure 3-5a, 3-5d).
Two IgG4-IgA2 lineages show a direct switch from IgG4 from IgA2 (Figure 3-8, 3-9), while
in the other case, the IgA2 switches from IgA1 and the IgG4 switches from IgG1 (Figure
3-5a). In both of these IgG4-IgA2 direct switches, the IgA2 clone remains anti-Dsg
reactive (Figure 3-21a).
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3.4.6 Anti-Dsg IgA1 Shows Close Relationships to Both anti-Dsg IgG1 B
Cells and anti-Dsg IgA2 by Direct Switch
After studying the relationships between IgG4 and each of the other three
subclasses, we next sought to apply the same analysis to the lineage relationships
between IgA1, IgA2, and IgG1. Interestingly, IgG1 and IgA1 show a direct switch in four
of six analyzed lineages in which they coexist. We also found that in two lineages
demonstrating an IgG1 to IgA1 switch, there is evidence of a subsequent switch to IgA2
with a few mutations (Figure 3-9, 3-10), suggesting that IgA1 can act as a hub for clonal
maturation from IgG1 to IgA2. There are no examples of direct IgG1 to IgA2 switching
present without IgA1 sharing the IgG1 sequence, implying the necessity of an IgA1
intermediate in this switch pathway.
The connection between IgA1 and IgA2 is particularly strong in the autoreactive
lineages we have studied, mirroring their high pairing rate in the global repertoire.
There is evidence of direct switch in 10/11 analyzed lineages in which IgA1 and IgA2 coexist. In the other case (Figure 3-16), the IgA1 and IgA2 appear on adjacent terminal
nodes, but show no direct switch. In total, of the 13 multi-subclass lineages containing
IgA2, 10 show a direct switch from IgA1 (two of which originate from a shared IgG1/IgA1
node), two show a direct switch from IgG4, and another demonstrates co-evolution with
IgA1.
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3.4.7 Repertoire Sequencing Effectively Captures Each Subclass’ Diversity
Our study indicates that the majority of anti-Dsg IgG4 B cells in PV do not
demonstrate lineage relationships to IgG1 or IgA. Our inability to identify IgG1-IgG4 B
cell lineage relationships or direct class-switches could be due to the fact that such
relationships simply do not occur, meaning IgG4 B cells are switching directly from
upstream non-IgG1 subclasses (IgM, IgG2, IgG3). Alternatively, we simply could have
failed to sample the IgG1 precursor of any given IgG4. Because we are able to identify
cross-subclass lineage relationships and ongoing class-switching for the majority of antiDsg IgA1 B cell lineages, a population that is likely as diverse in the circulation as IgG1,
and because we are able to find several instances of ongoing IgG1 to IgA1 classswitching, we find it unlikely that we lack the power to detect relevant class-switching
relationships between IgG1 and IgG4 due to undersampling. However, to address the
issue of potential undersampling of the circulating repertoire, we performed rarefaction
analysis and asymptotic estimation of sample coverage for each patient-subclass pair
(Figure 3-22). Asymptotic estimation of species richness (e.g. determining the total
number of lineages in the population by estimating how many lineages we would find
had we continued sampling indefinitely) shows that we have captured 71-97% total
estimated lineages present in each patient. Furthermore, we also determine the
percentage of total lineage diversity we have sampled using asymptotic estimation of
the Shannon diversity and Simpson index, which are used in ecology to determine the
diversity of common and dominant taxa in ecological samples. Looking across each
patient-subclass pair, we have captured 97-99.98% of the lineage Shannon diversity and
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99.6-100% of the lineage Simpson diversity, indicating we have sampled most of the
common and dominant antibody sequences from circulating IgA1, IgA2, IgG1, and IgG4
B cells in the repertoire.
To determine the relative contribution of technical and biological factors to
undersampling, biological replicates were performed for PV17 and PV18 by taking two
separate 30 mL blood draws, and for PV16, PV17, and PV18, each biological replicate
(one for PV16, two for PV17 and PV18) was sequenced twice as technical replicates to
determine the sufficiency of sequencing depth. Each pair of biological or technical
replicates were compared for overlapping lineages, and population size estimators were
used to determine what fraction of lineages were being captured (Table 3-5). After
filtering those lineages containing below five reads, mark-and-recapture analysis using
the Chapman estimator demonstrates that 96.57-99.97% of the lineages within a
sample are captured by pooled technical replicates, and over 35.46-81.99% of the
lineages within the circulation are captured by pooled biological replicates, suggesting
that most of the undersampling in the experiment is due to biological, rather than
technical, limits.

3.4.8 Epitope Mapping Shows N-terminal Preference of IgG4 Relative to
Other Subclasses
Our data have shown, with high confidence, that the anti-Dsg IgG4 repertoire
does not share lineage relationships or direct class-switch origins from IgG1 or IgA1. We
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have also demonstrated that the anti-Dsg IgG1, IgA1, and IgA2 repertoires often share
lineages separate from anti-Dsg IgG4. To determine whether this division in the
repertoire could be explained by differing epitope reactivity, we determined the Dsg
extracellular (EC) domain specificity of Dsg-reactive clones (Table 3-7)(226). Dsg-reactive
clones sharing a lineage mapped to the same epitope in all cases. The plurality of clones
within each subclasses demonstrated reactivity against the amino-terminal EC1, and in
aggregate, at least two Dsg-reactive clones react to each of the five extracellular
domains. However, there is a statistically significant shift towards EC1 reactivity in the
IgG4 subclass compared to all other subclasses (p = 0.009 by Fischer’s exact test). This is
especially pronounced when comparing IgG4 to the IgA subclasses, which show more
evenly-distributed reactivity to all five extracellular domains.

3.5 Discussion
Class-switching is largely directed by the cytokine milieu and T-cell help that a B
cell encounters during an ongoing immune response, where it serves to modify and
diversify the effector functions of antibodies. In this study, we have presented evidence
that despite co-occurring with several other subclasses and responding to the same
antigen, the IgG4 Dsg-reactive repertoire arises largely independently of the other
subclasses in a panel of PV patients. By cloning each subclass into a separate phage
display library, we have the ability to screen for rare autoreactive clones from more
infrequent B cell subclasses (like IgG4 and IgA2) at unprecedented depth, free of
competition from clones in more diverse subclasses. Furthermore, our sequencing
92

method managed to capture a majority of the total lineages in each sample, including in
particularly diverse subclasses like IgA1 and IgG1, allowing us to obtain a representative
picture of the class-switch landscape in the circulating B cell repertoire of PV patients.
Only a minority of detected Dsg-reactive IgG4 lineages also contain IgG1
sequences, with only a single lineage showing a direct switch between IgG1 and IgG4.
The existence of a switch pathway from IgG1 to IgG4 in the normal B cell repertoire was
characterized in a large-scale repertoire study of the human class-switching landscape,
with direct switches from IgM, IgG2, and IgG3 to IgG4 occurring at similar frequencies
(137). Due to their relative unimportance in PV, our study did not include IgG2 or IgG3,
leaving open the possibility of an IgG2 or IgG3 clone – most likely a non-reactive one during a switch to IgG4. Even given that caveat, our data suggest a mostly disjoint
relationship between the IgG1 and IgG4 anti-Dsg repertoires, in which both evolve
independently from different precursors and with IgG4 only rarely switching from IgG1.
Furthermore, only 28% of IgG4 belonged to multi-subclass lineages, and 4/6 lineages
containing confirmed reactive IgG1 and IgG4 clones showed early divergence between
the two, suggesting that even when anti-Dsg IgG1 and IgG4 share a lineage, they
develop largely independently within said lineage.
Sequences mapped to anti-Dsg IgG4 lineages showed significantly fewer
connections to other subclasses than IgA1, IgA2, or IgG1, suggesting a pathway in which
the majority of the Dsg-reactive IgG4 repertoire originates from a non-IgG1 subclass
(like IgM, IgG2, or IgG3), creating its own self-contained thoroughfare of autoreactivity
in the overall class-switching landscape. This is further supported by the fact that a
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majority of anti-Dsg3 IgG4 reverted to either their MRCA (2/3) or germline (8/11)
sequence remained reactive. A similar finding has recently been published for an
endemic form of pemphigus foliaceus found in Brazil (fogo selvagem); reversion of
mutations to germline in two clones found both of them to remain cross-reactive to
Dsg1 and the sandfly salivary antigen LJM11 (404). We have also previously found some
anti-Dsg3 IgG using the VH1-46 gene segment retain reactivity at germline (367). Of the
14 anti-Dsg3 IgG4 clones we have reverted, only one used VH1-46 (though it was
germline-reactive), demonstrating that the IgM repertoire may demonstrate a wider
range of Dsg reactivity than previously suggested. Further studies, including repertoire
cloning of IgM, IgG2, and IgG3, comparing germline-derived sequences from different
subclasses in the anti-Dsg repertoire in terms of polyreactivity, affinity, and epitope
preferences, and determining the integrity of central tolerance mechanisms in PV
patients, will shed more light on the divergent origins of Dsg-reactive IgG1 and IgG4.
Interestingly, though anti-Dsg IgG4 was the most solitary of all the anti-Dsg
subclasses, it demonstrated a noticeable increase in connectivity relative to the global
anti-Dsg repertoire – in fact, this increase in connectivity between subclasses in Dsgreactive lineages relative to the global repertoire occurs in all subclasses. Determining
whether this increase in connectivity occurs in any ongoing antigen-specific immune
response, or specifically in the context of PV or other autoantibody-mediated disease,
will require further study. Theoretically, an increase in subclass connectivity in an
antigen-reactive section of the B cell repertoire could simply reflect increased classswitching as part of an ongoing immune response. In the specific case of IgG1 and IgG4,
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however, this connectivity is not the result of direct switching between the two
subclasses, but due to lineages containing Dsg-reactive IgG1 and IgG4 sharing divergent
origins from precursors. Conversely, the connectivity in anti-Dsg IgA1-IgA2 shared
lineages seem to arise mainly from direct switching. This suggests that increased direct
switching is not the only mechanism increasing subclass connectivity in an ongoing
immune response. For example, it may be the case that IgM B cells with an intrinsic
propensity for switching divergently to different subclasses are specifically induced to
proliferate during PV, or that the cytokine milieu in PV specifically induces some IgM B
cells to switch to IgG1 and IgG4 independently, thus driving an increase in subclass
connectivity without an increase in direct-switch relationships.
The lack of identified precursor-product relationships between IgG1 and IgG4
may also be explained by the difficulty of capturing the full diversity of the human B cell
repertoire. Through mark-and-recapture analysis, we have shown that our approach is
primarily constrained by biological sampling. Although we used over 50 mL of blood
(approximately 1% of total blood) from each patient to maximize coverage, we are still
most likely missing rare circulating clones. This is made worse by the fact we may be
biasing against sequencing memory B cell clones due to the presence of highly
transcriptionally active plasmablasts “washing out” the mRNA contribution from
memory cells. Furthermore, there is the possibility of non-circulating related IgG1 B cell
clones occupying niches inaccessible to our sampling, or that hypothetical precursor
IgG1 are completely consumed by the switch to IgG4 and have disappeared from the
circulation by the time of disease onset. These caveats can be partly minimized due to
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our rarefaction analysis showing that we have effectively captured over 70% of lineages
in every sample, even in diverse subclasses, and by the fact that that we have found
robust evidence of direct switching between IgG1-IgA1, IgA1-IgA2, and IgG4-IgA2 as part
of an ongoing anti-Dsg response, making the absence of IgG1-IgG4 direct sequences
particularly conspicuous in this context, even given the constraints listed. Nevertheless,
given these caveats, it is entirely possible that longitudinal subclass-specific repertoire
studies in PV, or studies of the splenic, mucosal, and/or bone marrow repertoire in PV,
may reveal new relationships between subclasses that we are unable to detect in
peripheral blood.
The class-switch pathways leading to IgG4 are of fundamental interest not only
in the study of PV, but also the mechanism of several other autoimmune diseases (242)
and states of chronic antigen stimulation. Beekeepers (248), patients with chronic
helminth infections (252), and patients undergoing allergen desensitization therapy
(251) all develop IgG4, which serves as a blocking antibody to dampen the response to
the given antigen. In particular, novice beekeepers tend to show IgG1 to bee venom
antigens, while more experienced beekeepers who have been tolerized to bee stings
over time show IgG4 to the same antigens (256). Similarly, in fogo selvagem, healthy
people in the endemic focus often display anti-Dsg1 IgG1, whereas patients with active
disease display anti-Dsg3 IgG4 (405,406). A larger implication of the existence of
independent IgG1 and IgG4 anti-Dsg repertoires is that the reciprocal relationship
between IgG1 and IgG4 in some forms of chronic antigen stimulation may be due to
separate populations of B cells independently switching to IgG1 and IgG4 in response to
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antigen challenge, rather than direct switch between IgG1 and IgG4. It has been shown
that in allergen desensitization therapy and in tolerized beekeepers, the blocking IgG4 is
exclusively secreted by a population of IL-10 secreting regulatory B cells (407).
Expansions of regulatory B cells can be found in PV and other autoimmune conditions
(408,409); while we cannot draw conclusions about cell of origin from our experiments,
these data are which is mildly suggestive of the idea that pathogenic IgG4 in PV – and
protective IgG4 in other forms of chronic antigen stimulation - may arise from these
same cells developing independently of IgG1 responses to the same antigen. Single B
cell cloning experiments in PV patients targeting this population, or similar experiments
conducted longitudinally over a period of chronic antigen stimulation, will be able to
shed light on this hypothesis. Determining the developmental pathway of pathogenic or
protective IgG4 would lead to a better understanding of IgG4-mediated autoimmune
disease, allergen tolerization, and other IgG4-dependent processes.
We have also characterized, for the first time, the lineage relationships of IgA in
PV. We discovered a highly diverse IgA response to Dsg1 and Dsg3, which in several
lineages overlaps strongly with the IgG1 repertoire by direct switching from IgG1 to
IgA1. A high-throughput analysis of class switching recently showed that IgG1-IgA1
parent-child relationships are the second most common in the class-switching landscape
(137). Both the direct IgM to IgA1 switch and the sequential IgM to IgG1 to IgA1 have
previously been shown to be dependent on TGF-beta and CD40 activation in cultured
human B cells (410). IgA switching can also be triggered in a T-cell independent manner
on mucosal surfaces by TLR4 engagement and secretion of the cytokines BAFF and APRIL
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by dendritic cells (264). The role of TGF-beta in PV is not well-characterized; one study
found its serum levels elevated relative to controls (36), though others found otherwise
(411,412). Serum BAFF and APRIL also have an unclear role, having been found to be
elevated in bullous pemphigoid, but not PV (413,414).
Furthermore, we have characterized antigen-specific switching from IgG4 to IgA2
for the first time. The functional relevance of this switch pathway is unknown. 78% of all
IgA2-containing Dsg-reactive lineages were multi-subclass, and all except one of the 12
well-represented IgA2 multi-subclass lineage characterized shows a direct switch from
either IgA1 or IgG4, and the other lies close enough to IgA1 terminal nodes within the
tree to suggest that the an IgA1 to IgA2 switch probably occurred but wasn’t captured
by sequencing. IgA2 is the predominant IgA subclass in the mucosa (415). The
production of IgA2 is known to occur in the colonic lamina propria through secretion of
IL-10 and APRIL secreted from colonic epithelium in response to normal intestinal flora;
this occurs in both an IgM-to-IgA2 and IgA1-to-IgA2 fashion (91).
Given our results suggesting that anti-Dsg IgA clones either develop
independently from, or switch directly from, anti-Dsg IgG clones, and literature showing
that IgA-inducing cytokines have an unclear role in PV pathogenesis, it may be the case
that the existence of anti-Dsg IgA1 and IgA2 is simply a post-hoc epiphenomenon of PV,
catalyzed by the localized effect of IgA class-switch mediators like TGF-beta, LPS, BAFF,
or APRIL on Dsg-reactive IgM, IgG1, or IgG4. This seems especially likely for IgA2, as it
lies on the 3’ end of the IgH locus and therefore cannot serve as a class-switch
intermediate or harbor of pathogenic clones. It may be the case that the clones found in
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IgG1-IgA1 or IgG4-IgA2 parent-child pairs are cross-reactive to some antigen found in
the normal flora or present on mucosal surfaces. Somewhat suggestive of this possibility
is the fact that some anti-Dsg antibodies are cross-reactive to the rotavirus coat protein
VP6 (401). A circulating anti-Dsg IgG1 or IgG4 may enter a mesenteric lymph node or
Peyer’s patches in the lamina propria, where it is induced to switch from IgG1 to IgA1
(and, potentially, subsequently IgA2) or from IgG4 to IgA2 by the presence of said
antigen and a permissive cytokine milieu. The identity of said antigen(s) is beyond the
scope of this study, though it could be determined by targeted sequencing of the
mucosal IgA repertoire in PV and screening of anti-Dsg IgA clones for cross-reactivity
against a library of mucosal antigens found in normal flora.
In conclusion, it appears that in PV, the majority of anti-Dsg IgG4 B cells show no
evidence of arising from other subclasses, while anti-Dsg IgA1, IgG1, and IgA2 B cells
show more extensive relationships among each other. These results also imply that
sequential class switching is not a dominant pathway of IgG4 production in PV, despite
its temporal relationship with IgG1 in the setting of chronic antigen stimulation. Further
repertoire analysis and B cell lineage tracing in IgG4-centric conditions, like PV and other
states of continuous antigen challenge, would be needed to shed light on this claim.
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3.6 Figures and Tables
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Figure 3-22. Quantification of Sampling Coverage by Asymptotic Diversity Estimation.
Coverage is calculated by dividing the given diversity measure against the asymptotic estimation
of that measure, i.e. the value of that measure had we sampled each patient-subclass pair
infinitely. In this way, we can determine the percentage of the total of any given diversity
measure that we have captured. Results indicate that we have captured between 71-97% of the
species richness, meaning 71-97% of all lineages. The percentage of overall species richness
captured is lower than the percentage of Shannon or Simpson diversity captured, because
Shannon and Simpson diversity weight common species more than rare species.
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Table 3-1. Patient Characteristics. All ELISA and IIF results shown are reported from day of blood
draw.
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Library Name

PV8_IgA1
PV8_IgA2
PV8_IgG1
PV8_IgG4
PV8_CD8CD137
PV16_IgA1_techrep1
PV16_IgA1_techrep2
PV16_IgA2_techrep1
PV16_IgA2_techrep2
PV16_IgG1_techrep1
PV16_IgG1_techrep2
PV16_IgG4_techrep1
PV16_IgG4_techrep2
PV16_CD8CD137_techrep1
PV16_CD8_ctrl_techrep2
PV17_IgA1_biorep1_techrep1
PV17_IgA1_biorep1_techrep2
PV17_IgA1_biorep2_techrep1
PV17_IgA1_biorep2_techrep2
PV17_IgA2_biorep1_techrep1
PV17_IgA2_biorep1_techrep2
PV17_IgA2_biorep2_techrep1
PV17_IgA2_biorep2_techrep2
PV17_IgG1_biorep1_techrep1 §
PV17_IgG1_biorep1_techrep2
PV17_IgG1_biorep2_techrep1
PV17_IgG1_biorep2_techrep2
PV17_IgG4_biorep1_techrep1
PV17_IgG4_biorep1_techrep2
PV17_IgG4_biorep2_techrep1
PV17_IgG4_biorep2_techrep2
PV17_CD8_ctrl
PV18_IgA1_biorep1_techrep1
PV18_IgA1_biorep1_techrep2
PV18_IgA1_biorep2_techrep1
PV18_IgA1_biorep2_techrep2
PV18_IgA2_biorep1_techrep1
PV18_IgA2_biorep1_techrep2
PV18_IgA2_biorep2_techrep1
PV18_IgA2_biorep2_techrep2
PV18_IgG1_biorep1_techrep1
PV18_IgG1_biorep1_techrep2
PV18_IgG1_biorep2_techrep1
PV18_IgG1_biorep2_techrep2
PV18_IgG4_biorep1_techrep1
PV18_IgG4_biorep2_techrep1
PV18_CD8_ctrl_biorep1_techrep1
PV18_CD8_ctrl_biorep1_techrep2

amplicon
amplicon
amplicon
amplicon
control
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
control
control
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
control
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
amplicon
control
control

2 million
2 million
2 million
2 million
N/A
2 million
2 million
2 million
2 million
2 million
2 million
2 million
2 million
N/A
N/A
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
N/A
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
1 million
N/A
N/A

563,318
507,403
225,970
486,522
67,350
6,003,666
2,611,517
3,602,020
1,630,116
2,008,340
4,570,970
2,842,805
3,084,691
206,081
51,913
1,802,610
1493642
1,965,234
2230709
13,874
1122326
1,445,283
100511
1,445,283
1429640
2,631,760
1650619
942,375
1104639
6,339,392
1292417
13
1,420,051
1,581,038
2,415,204
2,401,631
1,828,683
1,795,421
1,445,333
1,410,673
1,828,764
1,781,258
2,170,890
2,124,189
3,220,473
971,354
153,710
145,523

539,718
498,078
218,382
480,065
67,223
5,281,921
2,047,919
3,022,902
1,395,739
1,623,057
3,815,672
2,572,873
2,508,222
202,484
48,110
1,125,364
1155602
1,169,651
1714022
8,974
836316
767,294
63859
767,294
1098648
1,468,403
1251274
576,758
886049
3,648,935
955255
10
1,060,437
1,342,842
1,964,802
2,091,333
1,551,086
1,600,299
1,191,743
1,231,317
1,491,920
1,549,026
1,732,124
1,814,548
2,900,754
638,340
138,980
138,980

95.81%
98.16%
96.64%
98.67%
99.81%
87.98%
78.42%
83.92%
85.62%
80.82%
83.48%
90.50%
81.31%
98.25%
92.67%
62.43%
77.37%
59.52%
76.84%
64.68%
74.52%
53.09%
63.53%
53.09%
76.85%
55.80%
75.81%
61.20%
80.21%
57.56%
73.91%
76.92%
74.68%
84.93%
81.35%
87.08%
84.82%
89.13%
82.45%
87.29%
81.58%
86.96%
79.79%
85.42%
90.07%
65.72%
90.42%
95.50%

397,937
356,840
182,244
252,811
8,647
3,153,655
1,251,719
2,119,503
870,472
1,168,644
2,183,580
1,627,421
1,434,574
24,424
7,460
796,089
739872
821,185
1042451
7,710
539151
560,457
52508
560,457
768376
1,090,179
800339
442,933
601436
2,538,537
648194
4
648,946
747,474
1,002,415
1,025,925
665,616
667,270
539,400
545,658
840,523
848,768
800,985
813,998
931,629
331,935
17,313
16,950

381,828
338,342
172,101
224,960
6,309
2,109,693
1,196,684
1,434,855
831,499
945,321
2,063,076
1,092,428
1,367,841
16,264
#N/A
687,339
693720
713,328
977047
6,839
501350
483,349
49837
0
720959
949,043
753002
394,834
574899
2,240,534
617939
#N/A
605,795
701,561
938,151
959,689
611,752
616,923
502,332
506,807
779,587
797,285
750,426
760,975
837,332
286,352
#N/A
#N/A

523,453
479,310
208,225
451,375
64,378
3,855,122
1,990,551
2,188,571
1,355,370
1,355,262
3,686,624
1,853,122
2,436,784
169,164
#N/A
1,004,456
1106200
1,050,710
1643832
8,070
796881
684,141
61167
0
1049606
1,315,863
1202106
525,251
858335
3,309,661
923926
#N/A
1,013,662
1,291,731
1,892,143
2,015,940
1,485,056
1,537,649
1,146,974
1,184,857
1,424,743
1,491,835
1,672,053
1,751,362
2,779,582
586,488
#N/A
#N/A

96.99%
96.23%
95.35%
94.02%
95.77%
72.99%
97.20%
72.40%
97.11%
83.50%
96.62%
72.03%
97.15%
83.54%
#N/A
89.26%
95.72%
89.83%
95.90%
89.93%
95.28%
89.16%
95.78%
0.00%
95.54%
89.61%
96.07%
91.07%
96.87%
90.70%
96.72%
#N/A
95.59%
96.19%
96.30%
96.39%
95.74%
96.09%
96.24%
96.23%
95.50%
96.31%
96.53%
96.52%
95.82%
91.88%
#N/A
#N/A

355,272
315,457
157,944
208,614
0
1,979,533
1,141,817
1,330,317
789,997
881,944
1,963,043
1,029,066
1,303,973
#N/A
#N/A
649,307
657,595
671,700
924,258
6,521
468,133
452,262
46,570
0
681,692
891,602
708,791
374,076
547,196
2,101,635
583,501
#N/A
570,752
664,692
887,075
909,378
574,778
581,051
470,218
475,524
725,059
743,819
693,900
705,391
782,488
259,329
#N/A
#N/A

93.05%
93.24%
91.77%
92.73%
0.00%
93.83%
95.42%
92.71%
95.01%
93.30%
95.15%
94.20%
95.33%
#N/A
#N/A
94.47%
94.79%
94.16%
94.60%
95.35%
93.37%
93.57%
93.44%
#N/A
94.55%
93.95%
94.13%
94.74%
95.18%
93.80%
94.43%
#N/A
94.22%
94.74%
94.56%
94.76%
93.96%
94.19%
93.61%
93.83%
93.01%
93.29%
92.47%
92.70%
93.45%
90.56%
#N/A
#N/A

IgA1
IgA2
IgG1
IgG4
#N/A
IgA1

IgA2
IgG1
IgG4
#N/A
#N/A
IgA1

IgA2

IgG1

IgG4

#N/A
IgA1

IgA2

IgG1

IgG4
#N/A
#N/A

40,429

98,798

29,696
#N/A
#N/A

89,211

65,812

89,860

44,451
24,600
40,253
9,935
#N/A

14,564

27,708

5,284
#N/A
#N/A

19,728

21,697

27,136

22,547
10,787
27,707
5,098
#N/A

32,045

41,675

86,916

13,018

140,192

39,037

26,691

9,966
#N/A

110,495

3,495
#N/A
#N/A

58,885
#N/A

10,682
#N/A
#N/A
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patientID Type ~# of Class-Switched B Cells # Total Read # Assembled Read % Assembled Reads # NR Tags # Isosignature Verified NR Tags # Isosignature Verified Reads ssembled Reads Passing Isosigna # IMGT Filtered NR Hits % IMGT Filtered NR Hits Ab Lineage Subclass # Clusters # Superclusters/Lineages
PV8
PV8
PV8
PV8
PV8
PV16
PV16
PV16
PV16
PV16
PV16
PV16
PV16
PV16
PV16
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV17
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18
PV18

§ PV17_IgG1 isosignature was labelled incorrectly, this replicate was discarded

Table 3-3. Sequencing Metadata.
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CHAPTER 4:

Discussion and Future Directions

4.1 Summary of Findings
We have elucidated the role of autoantibody subclass in pemphigus vulgaris by
determining the effects of the constant region on variable region affinity, specificity, and
blistering ability, as well as investigated the relationships between variable regions
across different subclasses in order to determine the class-switch pathways are most
relevant to disease. Our results have substantiated the idea that there are partially
disjoint sub-populations within the set of anti-Dsg antibodies in PV, partitioned by
preferred class-switch pathways – namely, a prominent IgA1 to IgA2 switch, a fairly
common IgG1 to IgA1 switch, and a notable, but not as prominent, IgG4 to IgA2 switch.
Notably minor was a direct switch connecting IgG1 and IgG4, the two subclasses
thought to be most important for disease, and the two subclasses that have a reciprocal
relationship during chronic antigen stimulation (which shifts from IgG1 to IgG4 in some
cases). Because both IgG1 and IgG4 are present during active disease, and IgG1
predominates during remission, we had hypothesized that the IgG4 and IgG1 could be
clonally related – our data instead suggests the idea that most anti-Dsg IgG1 and antiDsg IgG4 lineages do not overlap. This has implications not only on the pathogenesis of
PV, but on the development of the IgG4 repertoire in general. These results can help
understand IgG4-mediated autoimmune disease, allergen desensitization, and any other
process, pathological or protective, resulting in IgG4 production.
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While previous studies have shown that injection of anti-Dsg3 scFv or Fab was
sufficient to cause blistering in model systems, there remained the possibility that the
IgG1 or IgG4 constant region directly modulated the affinity or pathogenicity of an antiDsg antibody. By cloning several anti-Dsg3 variable regions onto both IgG1 and IgG4
constant regions, we managed to show that the constant region does not modulate the
blister-inducing ability, Dsg3 internalization ability, or epitope preferences of pathogenic
anti-Dsg3 antibodies. This suggests that a change in constant region from IgG1 to IgG4
alone is not sufficient to explain the pathogenic role of IgG4 autoantibodies in PV (see
chapter 2).
This result buttressed further investigation of the lineage relationships between
IgG1 and IgG4 in a panel of four PV patients (chapter 3). Through subclass-specific
repertoire cloning, we have shown that the IgG4 anti-Dsg repertoire in PV mostly
develops independently from the IgG1, sharing few lineages and few direct-switch
relationships. This was an unexpected finding; given the reciprocal relationship between
IgG1 and IgG4 over the course of disease in PV (IgG1 predominance during remission,
IgG4 predominance during active disease) and the arrangement of constant region
exons on the IgH locus, we expected to find that the majority of IgG4 clones switched
from IgG1 during active disease. We have also characterized the relationship between
IgA and IgG in PV for the first time, showing that IgA1, IgG1 and IgA2 often share clonal
lineages with each other, and that IgA subclasses appear to switch from IgG subclasses
(if they are related by direct switch at all), rather than the reverse. In particular, IgA1
and IgA2 in pemphigus are highly related, and some IgG1 share lineages with, or even
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directly class switch to, IgA1. Also notable is the lack of detected lineage relationships
between IgA1 to IgG4, casting doubt on the idea that the mucosal to mucocutaneous
disease course in PV is due to cross-reactivity hiding in IgA1. More generally, the fact
that switching seems to proceed in the IgG to IgA direction suggests that IgA is not
important for the ontogeny of PV, but may instead be an epiphenomenon or serve a
disease-modifying function, possibilities we discuss later in this chapter.
Our results suggest that there exist two major axes of class-switching in PV,
tracing two different paths through the antibody repertoire. First there is an
interconnected IgG1-IgA1-IgA2 repertoire reactive to a wide range of epitopes on the
Dsg molecule, and a solitary IgG4 +/- IgA2 repertoire tightly focused on the N-terminal
domains of Dsg. The implications of these newly-characterized lineage relationships in
PV, and in other will be discussed in the next sections.

4.2 Discussion and Future Directions
4.2.1 The Autoantibody Repertoire in PV is Highly Diverse
For the first time, we have categorized subclass-specific repertoires in
pemphigus vulgaris, managing to isolate an unprecedented 80 lineages worth of
validated anti-Dsg3 and anti-Dsg1 antibodies. Particularly notable is the fact that the
response is highly polyclonal, encompassing many different CDR3 sequences and VH
genes; this stands in contrast with the fact that some antigen-specific sequences appear
to be highly stereotyped and shared between patients (416). Repertoire studies of
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dengue fever (275), influenza vaccination (417), and HIV (418) have shown convergent
CDR sequences, and some autoantibodies show shared VH gene usage across patients
(419)(420)(421). Previous antibody cloning efforts in PV identified shared usage of the
VH1-46 gene segment between patients (367), and also found that some pathogenic
anti-Dsg antibodies share a D/E-X-X-X-W motif (209). In contrast, we only found VH1-46
antibodies in two of our four patients, only one of which had VH1-46 IgG. Furthermore,
there were no convergent CDR3 sequences between patients
Our results suggest that the response to desmoglein has the potential to be
much more polyclonal than initially anticipated, across all subclasses studied. Despite
this, the plurality of clones across the panel of patients seem to bind to the EC1 domain
of Dsg; this EC1 preference is particularly notable in the IgG4 clones. The reasons for this
are unclear; perhaps particular epitopes within the EC1 domain are more easily
displayed on dendritic cells or other antigen-presenting cells, or more easily shed into
the circulation and taken up by antigen-presenting cells after keratinocyte death (thus
triggering an immune response), or are particularly proficient at triggering an IgG4 class
switch pathway. More generally, it may still be the case that within each EC domain,
different subclasses preferentially bind to different amino acid residues. Finer mapping
using competition ELISA or hydrogen-deuterium exchange (422,423) may reveal that
IgG4 clones segregate to different epitopes in the EC1 and EC2 domain than N-terminalbinding IgG1, IgA1, or IgA2 clones, possibly explaining the relationship between IgG4
and disease activity. It would be particularly interesting, for example, if IgG4 clones
preferentially bound to residues critical for adhesion, while other subclasses did not.
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4.2.2 The Potential Role of IgA in PV
The possibility of cross-reactivity to mucosal antigens in PV has previously been
investigated by our laboratory in the context of the shared VH gene usage theory.
Because VH1-46 antibodies with low somatic mutation counts were found in several PV
patients (367), and the VH1-46 segment is also prominent in the response to rotavirus
(424), it was postulated that VH1-46 antibodies could be cross-reactive to both Dsg3 and
rotavirus coat protein; several such antibodies were isolated from a PV patient’s IgM
repertoire (401). The idea of an IgA origin of disease was also particularly intriguing
because a substantial portion of the mucosal repertoire has been found to be
polyreactive, suggesting that the tolerance mechanisms in the mucosal immune system
are somewhat relaxed to help fend off infection and keep commensal bacteria in check
(265,425,426). Our experiments have instead suggested that anti-Dsg IgG4 antibodies
likely do not originate from IgA1. This is not entirely unexpected - the IgA1 to IgG4
pathway is relatively rare, representing 4% of all direct switches to IgG4 in the classswitching landscape outlined by the Quake group (137), and had not been characterized
prior to that study. Furthermore, because IgA2 is distal to IgG4 on the IgH locus, IgA2
cannot be the origin of anti-Dsg IgG4.
Collectively, our experiments seem to demonstrate the opposite relationship –
that of at least some IgA clones switching from IgG clones. There is a demonstrable
parent-child relationship between some anti-Dsg IgG1 and some IgA1 in autoreactive B
cell lineages in PV, suggesting that at least part of the anti-Dsg IgA1 repertoire arises
directly from IgG1 through class switching. In vitro experiments have shown that CD40
133

engagement and TGFbeta can induce an IgM-IgG1-IgA sequential switch (410). In the
Quake dataset, the IgG1 to IgA1 class-switch pathway is the second most common in the
overall class-switching landscape, second only to the IgM to IgA1 switch (137).
Unexpectedly, our results also showed a close relationship between some antiDsg IgG4 and anti-Dsg IgA2 in PV. Such a relationship in the normal antibody repertoire
was first discovered earlier this year in the Quake dataset; across a panel of 22 patients,
totaling 120000 unique IgA2 sequences and 16000 unique IgG4 sequences, that study
found a total of two sequences identical between IgG4 and IgA2, making our finding all
the more remarkable (137). Because our protocols called for separately amplifying and
sequencing each subclass using hinge-specific amplicons, our experiment is particularly
well-powered to find potentially rare class-switch pathways like this one, compared to
previous studies. Whether this IgG4-IgA2 axis is equally prevalent in normal individuals,
or specifically upregulated in pathological states like PV or other IgG4-mediated
conditions, is unknown, and could be the subject of future subclass-specific repertoire
sequencing experiments.
It is also notable that the majority of characterized anti-Dsg IgA2-containing
lineages show direct switching from IgA1, which often occurs via a well-characterized
extrafollicular T-independent class-switch pathway induced by the secretion of APRIL
from intestinal epithelial cells, triggered by antigens from mucosal normal flora (91). The
possibility therefore exists that autoreactive IgA2 arises through both GC and
extrafollicular responses. However, because we have not tracked the cell of origin
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through its development, we cannot determine for sure which pathway gave rise to any
given anti-Dsg clone.
Collectively, these experiments suggest that anti-Dsg IgA are not the origin of
autoreactivity in PV, and that therefore the switch from IgG to IgA could simply be an
epiphenomenon triggered by the localized effect of IgA class-switch mediators and/or
cross-reactivity of anti-Dsg IgG clones to some unknown antigens present in the mucosa.
However, it raises the possibility that an IgG to IgA switch could serve a diseasemodifying function in PV. It would be interesting, for example, to determine by
immunostaining whether the IgA deposits in the skin of patients with neutrophilic
infiltrate belong to the IgA1, IgA2, or both subclasses. It would be even more interesting
to determine whether the IgA-secreting B cells creating those deposits switched from
IgG by repertoire cloning of IgA+ plasma cells. An IgG1 to IgA or IgG4 to IgA2 class-switch
would then be shown to be contributing to the painful inflammation experienced by PV
patients due to neutrophilic infiltrates.

4.2.3 The Relationship Between Antigen-Specific IgG1 and IgG4 in PV
The inverse relationship between IgG1 and IgG4 in the setting of chronic antigen
stimulation is well-characterized, but subclass-specific repertoires have not extensively
been analyzed in this context. The Quake dataset suggests that approximately 25% of all
class switches leading to IgG4 originate in IgG1, while the plurality (38%) originate in
IgG2 (137). Our results indicate that rather than a sequential switch, it appears to be the
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case that anti-Dsg IgG1 and IgG4 exist in independent lineages, with the latter emerging
during active disease.
A priori, there exist three possibilities for the relationship between anti-Dsg IgG1
and IgG4: direct switch from IgG1 to IgG4, independent switch from common
precursors, or independent evolution. Of 39 anti-Dsg IgG4-containing lineages found by
our study, 8 of them contain both IgG1 and IgG4 sequences, and only one of them
displays and IgG1 to IgG4 direct switch. Taken at face value, this seems to suggest that
the majority (31/39) of anti-Dsg IgG4 arises completely independently of IgG1, a small
minority arises through direct switch (1/39), while the rest share common precursors
with IgG1 without displaying a direct switch. In contrast, there exist 30 anti-Dsg IgA2containing lineages; 21 of them contain IgA1 reads. Furthermore, of the 11 lineages
containing IgA1 and IgA2 reads that we subjected to phylogenetic analysis, 10 of them
showed a direct switch from IgA1 to IgA2.
Because we robustly detect overlap between two subclasses (IgA1 and IgA2) and
by contrast, do not detect it in another pair (IgG1 and IgG4), our data suggests we are
sufficiently powered to detect multi-subclass anti-Dsg lineages in PV. This suggests that
at the level of our sampling, the IgG1 and IgG4 anti-Dsg clones are disjoint compared to
IgA1 and IgA2; in particular, we have demonstrated that anti-Dsg IgG4 preferentially
segregates into single-subclass over than multi-subclass lineages compared to the other
three subclasses we have analyzed (see Figure 3-3D).
However, we cannot conclusively conclude that there do not exist IgG1 relatives
for anti-Dsg IgG4 clones, for two overarching reasons. First, sufficient sampling of the B
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cell repertoire by sequencing is an issue. While rarefaction analysis indicates that the
repertoire sequencing has sampled over 70% of the lineages in the peripheral
repertoire; however, we have only drawn 1% of the total peripheral blood, and only 2%
of a human’s B cells are circulating at any given time (46); there is always the possibility
that the IgG1 relatives (either IgG1 precursors of IgG4 or IgG1 shared or of our detected
anti-Dsg IgG4 clones simply have escaped sequencing, either because they are
circulating and not captured or because they are residing in a secondary lymphoid organ
and thus cannot be sampled by a blood draw. A repertoire-cloning experiment that
sequences several more biological replicates of blood and obtains tissues from other
organs (spleen, MALT, skin-draining lymph nodes) would improve the chances of
capturing these putative IgG1 relatives. Related to this is the issue that, because the
experiments sampled directly from whole PBMC RNA, we are probably overrepresenting transcripts from plasmablasts, which dilutes the contribution from
memory B cells and therefore make them less likely to be captured by our amplification.
To counteract this issue, future repertoire studies could bulk sort memory and
plasmablasts separately (or sort single B cells), and prepare sequencing libraries from
them independently, which would ensure that plasmablast RNA does not swamp out
the contribution from memory B cells. Second, there is the possibility is that IgG1
precursors or relatives no longer exist; they may have existed only as transient
intermediates during an IgM to IgG1 to IgG4 switch. Future experiments could solve this
issue by longitudinally cloning subclass-specific repertoires during disease onset and
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remission, though even this may not capture transient IgG1 intermediates if they don’t
circulate for sufficient duration.
There are also some drawbacks to the phage display technique worth
considering as a source of error or undersampling. First is the issue of light chains, which
presents several caveats. Even though we can screen between 100 million and 1 billion
transformants per patient-subclass pair, the random pairing of heavy and light chains
may have failed to pair some reactive heavy chains with compatible light chains. This
leads to the possibility that there exists some related IgG1-IgG4 pair that wasn’t
sampled in either the IgG1 or IgG4 libraries, and therefore wasn’t analyzed. This can be
solved by constructing multiple libraries from a single patient-subclass pair and panning
them independently, increasing the chances that a given anti-Dsg heavy chain pairs with
a permissive light chain. Alternatively, a future study could use a technique that
preserves heavy-light pairing (for example trapping individual cells in emulsified droplets
(427)), perhaps coupled to a flow-cytometry-based technique for sorting single B cells
for Dsg-reactivity; this would ensure that every heavy chain is screened while expressed
alongside its cognate light chain, eliminating the question of whether an in vivo reactive
heavy chain is missed.
There is also the possibility that some of our anti-Dsg antibodies primarily gain
their reactivity from their light chain, rather than their heavy chains. While antibodies
generally make most of their contacts through heavy chain CDR residues, there are
examples in the literature where antigen recognition is encoded by the light chain
(428)(429). In many cases, we found several anti-Dsg reactive heavy chains bound to
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different light chains, suggesting that the heavy chain remains the most important
determinant in binding in many cases; however, it may be the case that some of our
anti-Dsg heavy chains actually have no anti-Dsg activity in vivo and are therefore
irrelevant to disease, due to all anti-Dsg activity being mediated by the (mispaired) light
chain. The methods outlined above, which preserve heavy-light pairing, would mitigate
the possibility of irrelevant heavy chains entering the analysis.
Another overarching issue is that phage display is designed to find a particular
type of antibody, rather than sample the full breadth of response to a given antigen.
Phage display is optimized to find high-affinity clones, and in particular our stringent
washing procedures may be selecting for high-affinity clones with slow disassociation
rates. This has a few implications. First, high-affinity clones may be out-competing
disease-relevant low-affinity clones binding to the same epitope, or simply due to highaffinity clones dominating growth during phage amplification. There may be entire
lineages of disease-relevant low-affinity clones missed by our panning for this reason.
Amplifying and panning the unbound phage from each round, or decreasing washing
time, may pick up some of these low-affinity binders. Furthermore, it may be the case
that disease-relevant antibodies derive their high affinity from short association rates,
rather than long dissociation rates. Antibodies with short association rates could
theoretically be found by decreasing the initial incubation time of the library, which
would favor clones that quickly associated with Dsg.
Another drawback of our pipeline is that is that some positive clones may be
toxic to phage or bacteria, meaning they fail to amplify during panning or may confer
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growth disadvantages to the phage and will therefore be out-competed (430). Even
small differences in growth rate in a library can lead to dropout of positive binders
(431), suggesting that our screen may be missing several clones. This is further
exacerbated by the fact that about half of the scFv that we attempted to produce in this
experiment did not express in sufficient quantities for characterization, possibly due to
aggregation or toxicity; this may be mitigated by expression and screening in eukaryotic
systems. Another way to circumvent this issue is by using alternate screening
technologies, like antigen-specific B cell sorting (432), yeast display (433), ribosome
display (434), or mammalian cell surface display (435).
Given these caveats, it may be the case that we are missing certain relevant antiDsg antibodies and relatives in our samples. However, given the fact that our sampling,
both through phage display and through sequencing, was sufficient to show that direct
class-switching between anti-Dsg IgG1 and IgG4 in the periphery is not the predominant
pathway of IgG4 production. The larger implications of this fact will be discussed in the
next section.

4.2.4 Mechanisms of PV Pathogenesis and Their Larger Implications
The predominance of antigen-specific IgG4 in PV during active disease mirrors
several other conditions, including other antibody-mediated autoimmune diseases (242)
and subjects undergoing continuous antigen challenge, like allergen desensitization
therapy (255,436), helminth infection (249)(437), and continuous exposure to bee
venom antigens (248). In particular, an IgG1 to IgG4 shift occurs in beekeepers
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undergoing repeated challenge by bee venom antigens; tolerant beekeepers produce
IgG4 against bee venom from IL-10 secreting regulatory B cells, which dampen allergic
reactions (407). Because IgG4 has no effector function, it is believed to serve as a
“brake” on the immune response, competing with the binding of antibodies from other
subclasses (253)(252). Further evidence for this fact includes that the regulatory
cytokine IL-10 is responsible for biasing class-switch to IgG4 over IgE (438); this further
suggests that the aforementioned IL-10 secreting B cells will bias other B cells to switch
to IgG4 in the setting of chronic inflammation.
Because of the temporal relationships between IgG1 and IgG4 in endemic PF
triggered by continuous exposure to sandfly antigens (404)(406)(439) and in
beekeepers, as well as the presence of IgG1, but not IgG4, in some healthy relatives of
PV patients (246), it is tempting to suggest that PV arises by a similar mechanism of
chronic antigen stimulation, though rather than some external antigen it could be Dsg
doing the stimulating. Perhaps, for example, continuous shedding of Dsg3 extracellular
domain from apoptotic keratinocytes, which is then taken up and presented in skindraining lymph nodes by Langerhans cells, cross-reactive B cells, or other antigenpresenting cells, eventually leads to a germinal center response in genetically
susceptible individuals. Possibly suggestive of this, studies have found that
polymorphisms in the pro-apoptotic molecule ST18 are associated with PV in some
populations, and that ST18 is expressed at higher levels in the skin of PV patients
compared to controls (440)(441). Also suggestive is the fact that HLA-susceptible
individuals sometimes have circulating autoreactive T cells; in particular, some HLA141

susceptible individuals without disease seem to almost exclusively show autoreactive
Th1 cells, while those with disease show both autoreactive Th1 and Th2 (442); this is
concordant with the fact that IgG4 class-switch occurs in response to Th2 cytokines like
IL-4 and IL-13 (443). This low-level stimulation over a lifetime would then trigger the
switch to IgG4-secreting regulatory B cells, just like in beekeepers and the allergendesensitized – however, rather than the IgG4 serving a protective role, it actually is the
hallmark of active disease, causing blistering and pathogenesis rather than dampening
the response as it has evolved to do. Repertoire cloning from regulatory B cell subsets
could determine whether this portion of the mechanism is plausible; if, like in allergen
desensitization therapy and in beekeepers, the anti-Dsg IgG4 is exclusively secreted by
regulatory B cells, this would suggest a shared mechanism between these situations.
While the idea of continuous self-inoculation by Dsg resulting in disease is a
plausible model, there are other possibilities for the shift to IgG4 that don’t involve a
direct response to chronic antigen stimulation. For example, a normally protective IgM B
cell cross-reactive to both Dsg and some pathogen could be induced to switch to IgG4 in
the presence of a permissive Th2 cytokine milieu, rather than responding to Dsg
directly; this appears to be the mechanism in endemic PF, in which persistent challenge
with sandfly antigens leads to IgG4 that is cross-reactive to Dsg1 (404). This possibility is
particularly raised due to the cross-reactivity of VH1-46 IgM antibodies cloned from PV
patients to both Dsg3 and the rotavirus protein VP6 (401); however, because we have
determined that the anti-Dsg response is not VH restricted, such a single inciting event
of cross-reactivity may not be sufficient to explain all instances of PV. It would be
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intriguing, however, if cross-reactivity shaped and modified the response in some way. It
is possible that, for example, IgG1 and IgG4 that arise from common precursors due so
due to cross-reactivity of their IgM precursors to some pathogen (followed by a Th2
response that leads the same IgM B cell to switch independently to IgG1 and IgG4).
Further testing of germline IgG4 and IgG1 precursors for polyreactivity or crossreactivity to pathogens is necessary to determine whether this is a feasible outcome.
If PV, in fact, arises through the same mechanisms as other forms of chronic
antigen stimulation, the largely disjoint lineage relationship between IgG1 and IgG4 we
have characterized in PV suggests that chronic antigen stimulation could lead to the
production of circulating IgG4 plasma cells directly from IgM, IgG2, or IgG3, which like
IgG1 lie 5’ to the IgG4 constant region on the IgH locus. These results also have
implications for other IgG4-dominant autoimmune diseases and the IgG4 response to
chronic antigen stimulation. It would be interesting, for example to longitudinally clone
IgG1 and IgG4 in beekeepers to determine whether they share a lineage or arise
independently, which would answer a fundamental question about the immune
system’s self-limiting response to constant antigen challenge. Determining the cell of
origin, lineage, and maturation pathways of IgG4 in different types of chronic antigen
stimulation, for example, could lead to therapeutics that specifically up-regulate (in the
case where it’s protective, i.e. allergen desensitization therapy) or down-regulate (in the
case where it’s pathogenic, i.e. PV and other IgG4-mediated autoimmune diseases) the
IgG4 response in these situations, leading to more targeted therapies against
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pathogenic IgG4-mediated conditions and superior responses to existing therapies that
require an IgG4 response.
Confirming this idea of two separate switch pathways for the majority of IgG4
and the majority of IgG1 will require subclass-specific repertoire sequencing of IgG2 and
IgG3 in PV patients; there remains a possibility that affinity maturation and class
switching from these subclasses is the true origin of anti-Dsg IgG4, though this appears
unlikely due to the lack of involvement of these subclasses in disease. Ruling those out
at intermediates would then suggest that IgG4 originate directly from IgM. It would then
be very interesting if in their germline configuration, anti-Dsg IgG4 clones show altered
affinity, epitope coverage, and/or polyreactivity relative to anti-Dsg IgG1 germline
sequences. Our experiments showed significant germline and early reactivity to Dsg in
IgG4-containing lineages, suggesting that there is broader potential for naïve B cell antiDsg reactivity than previously appreciated, and that IgG4 may arise from such anti-Dsg
IgM clones.

4.3 Summary
This thesis has sought to answer the question of whether autoreactive IgG4 B
cells arise from other autoreactive subclasses in PV. More broadly, we have asked the
question: what are the clonal relationships between autoreactive B cells belonging to
different subclasses in PV? We have provided compelling evidence that autoreactive
IgG4 clones in PV largely do not share lineages with other subclasses, suggesting that
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IgG4 in other settings may also arise independently. This has implications on the
pathogenesis of other IgG4-mediated autoimmune disease and on the mechanism
behind the response to chronic antigen stimulation in general. Future experiments
should focus on generalizing this result to include more patients and more subclasses,
on testing the implications of this result for IgG4 responses in the setting of chronic
antigen stimulation or autoimmune disease, and on further characterization of germline
and somatically mutated intermediates in established anti-Dsg lineages to better
understand the evolution of the autoreactive B cell repertoire in PV and the IgG4
repertoire in general.
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